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ABSTRACT OF DISSERTATION 
 
 
 
SIGNALING MECHANISMS INVOLVED IN THE GENERATION OF HUMAN 
PERIPHERAL iTREGS  
 
Maintaining balance in the human immune system is critical for the body’s ability 
to discriminate between foreign and self-antigens. This balance is achieved, in part, by a 
subpopulation of T cells known as induced regulatory T cells (iTregs). Dysregulation of 
this population may contribute to the onset and progression of cancer, chronic 
inflammation and autoimmune diseases. Therefore, manipulation of iTreg development 
holds promising therapeutic potential; however, studying this vital population has proven 
difficult due to low numbers, heterogeneous cell populations, substantial phenotypic 
differences between mouse and human cells, and the high plasticity seen in iTregs. These 
current limitations have prevented a full understanding of the molecular signaling events 
that govern their development and function. Our lab has established a novel cell culture 
system that mimics in vivo human iTreg development. This system allows for the 
discrimination and comparison of naïve, memory and iTreg T cell populations 
simultaneously within a single donor. These iTregs exhibit high levels of CD25, FoxP3, 
CTLA4, GITR, low levels of CD127 and display strong suppressor activity. Using this 
innovative system, we have demonstrated a rewiring of T cell receptor (TCR) signaling in 
iTregs compared to conventional T cells. We found that the voltage gated K+ ion 
channel-Kv1.3 is not active in response to TCR engagement in iTregs, even though Ca2+ 
influx remains intact. Kv1.3 and the linked Src-family kinase Lck were redistributed to 
the highly active IL2-Receptor (IL2-R) complex. Additionally, we have shown that there 
is increased AKT protein expression in iTregs versus conventional T cell populations that 
does not correlate with the TCR-induced increase in its active (phosphorylated) form. 
This blockage appears to be due to an imbalance of kinase to phosphatase activity in 
iTregs with a specific TCR-induced inhibition of mTOR activity. We have also 
demonstrated that AKT accumulation in iTregs leads to its physical association with 
SMAD3, suggesting a novel, non-enzymatic function of AKT through transcription factor 
 
 
inhibition. This study sheds light on the reciprocal cross talk between the IL-2R and TCR 
signaling pathways and uncovers the mechanism of AKT blockade in primary human 
iTregs, thus opening novel avenues for therapeutic manipulation. 
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Chapter 1: INTRODUCTION 
 
All higher organisms are challenged by pathogens in their surrounding 
environment continuously attempting to invade the body ultimately resulting in an 
imbalance of immune homeostasis. Adding to the complexity of the interaction between 
the host and invasive organisms, higher organisms naturally support commensal bacteria 
at mucosal surfaces and skin through a highly evolved and specific symbiotic 
relationship.  This commensal relationship requires the ability to distinguish between 
desirable and undesirable microorganisms in order to favor the survival of beneficial 
symbionts and simultaneously eradicate pathogenic organisms. The human immune 
system consists of a variety of cell populations each contributing to the tolerance of self 
and symbiotic cells and to the defense against foreign pathogens.  It can generally be 
divided into two distinct, yet complementary subdivisions: innate immunity and adaptive 
immunity. The innate division of the immune system generates the first line of defense 
against an infection or insult by reacting to pathogens in a non-specific but rapid manner.  
Cells of the innate immune system typically respond to pathogen-associated molecular 
patterns (PAMPs) expressed by infectious agents that are conserved across groups of 
microscopic organisms and are not generally specific to species or strain. Conversely, the 
adaptive response requires an antigen-specific recognition of pathogens that can take 
several weeks to develop.  Though the generation of a primary adaptive immune response 
is slow, it generates a long-term protective memory that enables a rapid response upon 
additional encounters with a pathogen bearing an identical antigen. The adaptive immune 
response can be further subdivided into two types: humoral, which is mediated by B cell-
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produced antibodies; and cell-mediated, which involves the generation and activation of 
antigen specific T cells. Combined with the innate immune response, both humoral and 
cell-mediated adaptive responses are essential for the immune system as a whole to fight 
off invading pathogens. 
 
1.1 T lymphocytes – Effector T cells 
 The vital function of T cells in the defense against foreign pathogens is most 
potently demonstrated by a loss or defect in T cell populations which leaves individuals 
more vulnerable to infections.  Two major subsets of peripheral mature T cells can be 
identified by their mutually exclusive expression of cluster of differentiation (CD)8 and 
CD4 cell surface molecules (1). Most CD8+ T cells display cytotoxic effector function 
once activated in which they induce cell death in host cells infected with a pathogenic 
microorganism. CD8+ T cells recognize and lyse cells expressing the pathogenic antigen 
associated with major histocompatibility complex (MHC) class I molecules. On the other 
hand, CD4+ T cells recognize foreign antigens in the context of class II self MHC, which 
enables them to respond primarily to professional antigen presenting cells (APC). Once 
activated, most effector CD4+ T cells become helper T cells (TH cells) that provide 
essential additional signals to activate and direct other cells to respond aggressively to an 
infectious agent (2). Historically, CD4+ TH cells were classified as TH1 or TH2, however 
recently a switch to characterization of TH cells based on their cytokine expression 
signature has gained popularity. TH1 cells participate in cell-mediated immunity and are 
critical for the control of intracellular pathogens such as viruses and certain intracellular 
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bacteria through the production and secretion of interferon (IFN)-γ and tumor necrosis 
factor beta (TNF-β) (3). TH2 cells direct B cell activation and antibody production as well 
as basophilic and eosinophilic inflammation through the secretion of Interleukin (IL)-4, 
IL-13 and IL-5 (3). TH17 cells function to protect skin surface and intestine against 
extracellular bacteria through the production and secretion of IL-17 (4). All TH cell 
subsets listed above play a critical role in specific recognition of and in organizing a 
response against foreign pathogens. Though classic definitions of T cell lineage 
commitment are still in widespread use, the status quo has recently been challenged by 
evidence highlighting functional and developmental plasticity of T cells.  These recent 
studies clearly demonstrate that T cells exhibiting an individual TH subset phenotype are 
able to transition between TH lineages when needed and when in the presence of a 
cytokine milieu permissive to the transition (5).  Effector T cells form an integral part of 
the immune response that maintains flexibility to adapt to the ever-changing immune 
homeostatic balance. 
1.2 Regulatory T cell subsets 
Overactivation of effector T cells in the immune system can lead to an excessive, 
pathological inflammatory response and/or to autoimmune disease (6). Maintaining a 
balance between effective immune response and peripheral tolerance is achieved, in part, 
by regulatory T cells (Tregs) (7, 8) through direct cell to cell contact, soluble factors, 
metabolic disruption or indirect effect mediated by dendritic cell (DC) suppression (9-
11). First known as “suppressor” cells, for over a decade it remained unclear the true 
identity of these anti-inflammatory cells due to an inability to distinguish them from other 
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conventional T cells. A turning point of Treg research came in 1995 when the link 
between suppressor function and cells that expressed high levels of the IL-2 receptor 
alpha chain (CD25) was made (12). Additionally, in 2003 the identification of the 
forkhead winged helix transcription factor (FoxP3) as a critical regulator of Treg 
development and function helped to establish a Treg phenotype (13-16). Deficiencies in 
FoxP3 underlie the lymphoproliferation and multiorgan autoimmunity of scurfy mutant 
mice and human patients with Immunodysregulation Polyendocrinopathy and 
Enteropathy, X-linked syndrome (IPEX) (17, 18). IPEX usually affects males causing 
them to rarely live beyond infancy and to suffer from severe enlargement of the 
secondary lymphoid organs, insulin-dependent diabetes, eczema, food allergies and 
concomitant infections (19). Despite their critical involvement in immune homeostasis, 
Tregs constitute only about 1-5% of the circulating T cells in the human body. Two main 
subsets have been distinguished according to their origin: naturally occurring, thymically 
selected natural Tregs (nTregs), and peripherally induced Tregs (iTregs) differentiated 
from circulating conventional CD4+ T cells. These two subsets are phenotypically 
indistinguishable in their high expression of CD25, cytotoxic T lymphocyte antigen 4 
(CTLA4), glucocorticoid-induced tumor necrosis factor receptor (GITR) and FoxP3, and 
lack of the alpha chain of the IL-7 receptor (CD127). Unfortunately, despite intensive 
research, there are still no definitive surface or intracellular markers that clearly 
distinguish Tregs from conventional T cells in humans, although nTregs differ from 
iTregs in a variety of ways (Table 1). While high affinity interactions with cognate self-
peptide-MHC complexes and strong CD28 co-stimulation drive the development of 
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nTregs, iTregs require weaker, suboptimal T cell receptor (TCR) stimulation and can be 
generated in the absence of CD28 co-stimulation (20). In addition, differentiation of 
iTregs, but not nTregs, requires IL-2 and transforming growth factor-β (TGF-β) (21). 
nTregs develop a TCR specificity for self-antigens in the thymus whereas the iTreg 
repertoire is more specific for tissue and foreign antigens (20). This dichotomy may 
account also for their different regulatory activities, with nTregs preferentially involved 
in preserving self-tolerance and iTregs being more functionally active at inflammatory 
sites.  
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Table 1. Comparison of nTregs and iTregs. 
        
Modified with permission from (20, 21).   
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Careful attention must be paid to the differences between mouse and human 
Tregs. While FoxP3 is considered the definitive marker for mouse Tregs, the expression 
of FoxP3 in human is not confined to Tregs, but can be also induced in activated, 
conventional T cells (22). This observation added further confusion as to whether 
circulatory FoxP3+ Tregs are thymic in origin and persist in the periphery, or whether 
they are induced during antigen-specific stimulation (23).  
Key evidence for the relevance of peripheral generation of human Tregs came 
from the work of Vukmanovic-Stejic et al. The authors proposed that antigenic 
persistence induces a continuous generation of short-lived and prone-to-apoptosis Tregs 
from a population of rapidly dividing, highly differentiated memory CD4+ T cells (24, 
25). Since the number and function of CD4+CD25+FoxP3+ Tregs is maintained even 
during senescence in humans (23),  thymic nTregs cannot account for the lifelong 
existence of human Tregs supporting the hypothesis that Tregs in adult humans develop 
from a pool of circulating peripheral T cells. Recent evidence emphasizes plasticity of TH 
cells, with this in context, iTregs can be generated from TH1, TH2, and TH17 effector 
cells as well as from naïve cells (26) (Figure 1.1). In fact, CD103+ DCs from the 
mesenteric lymph nodes can induce the differentiation of naïve CD4+ T  cells into iTregs 
in the mucosal environment of the gut, providing a mechanism by which functionally 
specialized gut-associated lymphoid tissue DCs can extend the repertoire of Treg cells 
(27). These findings are consistent with iTreg differentiation being tailored according to 
specific microenvironment requirements, thus ensuring the physiological ability to 
control immune homeostasis when and where needed. In addition to their critical function 
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in maintaining immune homeostasis after infection or inflammatory response, iTregs are 
also considered major contributors to the failure of immunosurveillance during cancer 
progression as the tumor microenvironment is especially favorable for the generation of 
iTregs (28).  
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Figure 1.1 
 
Figure 1.1: Origin and maintenance of peripheral CD4+CD25- Treg cells.  
Naturally occurring thymic-derived regulatory T cells (nTregs) develop in thymus as a 
separate lineage but display limited capacity for self-regeneration. Therefore, peripheral 
Treg homeostasis is likely to be preserved by the continuous production of Tregs from 
another population. Experimental evidence supports the prevalence of the newly 
generated iTreg in the maintenance and control of peripheral Treg homeostasis (23). 
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This high degree of developmental plasticity in iTregs also makes them 
functionally unstable. Xu et al. (29) and Yang et al. (30) each found independently that a 
fraction of peripheral FoxP3+ T cells lose FoxP3 expression and produce IL-17 upon in 
vitro stimulation in the presence of IL-6. Also, when highly purified FoxP3+ cells were 
transferred into RAG-/- mice, approximately half of the cells lost their FoxP3 expression 
and  produced IFN-γ, IL-2 and IL-17 (31, 32). In addition, FoxP3+ T cells may acquire 
TH cell features without losing FoxP3 expression. These hybrid FoxP3+RORγt+IL-17+ or 
FoxP3+T-bet+IFN-γ+ cells have been characterized as being in a transitional state between 
Treg and TH phenotypes (33). The issue of Treg plasticity is controversial and it remains 
to be established whether it reflects true lineage reprogramming of committed Tregs or is 
a dynamic transition of an uncommitted population of FoxP3+ T cells (34). This high 
degree of plasticity in the iTreg developmental program represents an additional 
challenge to the inherent difficulties associated with the study of human Tregs, such as 
small numbers of cells, impure populations and phenotypic differences between animal 
and human models, which is particularly important when considering Tregs in therapeutic 
treatment for human disease. These intrinsic limitations have prevented a comprehensive 
understanding of the differential signaling events that govern the development and 
function of Tregs. 
 
1.3 Link between dysregulation of Tregs and human disease 
 Dysregulation of the Treg population has been implicated in autoimmune and 
chronic inflammatory diseases, infections and cancer (35). Therefore understanding the 
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link between the role of Tregs and the disease onset will be critical for treatment. In 
multiple sclerosis (MS), controversial results have been published on the role of 
CD25+FoxP3+ Tregs. The level of Tregs in the blood of MS patients and healthy controls 
were compared and found to be either normal or decreased in MS patients (36-39), 
however others have postulated that even if the frequency of Tregs is normal, the cells 
may not be functioning normally and are unable to control the activation and proliferation 
of the pathogenic T cells (40). Recently, Dalla Libera et al. found that Tregs were 
significantly decreased in stable MS patients but were restored to normal levels during an 
acute attack, suggesting that the role of Tregs is to react to the inflammation during a 
relapse and not necessarily the cause of the relapse (39). It is clear that Tregs do 
contribute to the disease in humans, but the extent of their involvement needs to be 
further investigated. Inflammatory bowel diseases (IBD) like ulcerative colitis and 
Crohn’s disease have also been linked to dysregulation of Treg populations (41). IBD is a 
family of chronic diseases characterized by infiltration of inflammatory cells into the 
lamina propria of the intestinal tract. Patients with IBD appear to have relatively reduced 
numbers of Tregs in the blood and in the colon; however these Tregs still appear to be 
functional in vitro (41). Additionally, it has been found that in the experimental model of 
diabetes using NOD mice, treatment with islet-specific Tregs can block diabetes months 
after initiation, suggesting that the endogenous Treg cells could be dysfunctional leading 
to the onset of the disease (42). Systemic lupus erythomatosus (SLE) and rheumatoid 
arthritis (RA) both arise due to a failure of immunological self-tolerance and have both 
been link to deficiencies in the Treg population (43). In RA it is has been found that there 
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are relatively normal levels of Tregs in the patients, but that the pathogenic T cells in the 
microenvironment do not appear to be responsive to Treg suppression (44). Lastly, in 
graft versus host disease, treatment with Tregs  has also been found to be beneficial in 
limiting the disease lethality (45). These studies implicated that regulatory T cell 
development, control and function may offer insight into the onset and treatment of 
autoimmune and chronic inflammatory diseases, asthma and cancer.  
 
1.4 T cell receptor signaling     
 To sense the changes in their surrounding microenvironment, T cells utilize a 
variety of specialized cell membrane receptors that interact with ligands in the local 
milieu. The ligand-receptor interaction initiates a chain of intracellular biochemical 
reactions –pathways that relay, amplify and distribute those initial signal inputs into the 
cell. Cross talk among multiple, simultaneously active pathways, together with positive 
and negative feedback activation loops, produce a complex signaling network that is 
tightly coordinated and integrated to summon the adequate cell response. This response is 
elaborated in the cell nucleus and mediated by the action of transcription factors through 
the regulation of gene expression and protein synthesis (6). T cell activation begins with 
the specific recognition of antigen displayed on MHC heterodimers on the surface of 
antigen presenting cells by the TCR (Figure 1.2) (46). The TCR is anchored in the cell 
membrane and consists of two chains alpha (α) and beta (β). TCR associates into a 
complex with other molecules like CD3, which possess distinct chains (γ, ζ, δ and ε). 
Engagement of the TCR, as well as other co-stimulatory receptors on the T cell like CD-
13 
 
28, with the APC triggers a rearrangement of the T cell membrane and the formation of 
the immunological synapse (47). The binding of the TCR to MHC/antigen complex to the 
TCR complex leads to a conformational change in CD3ζ, allowing the protein tyrosine 
kinase Lck to phosphorylate the immunoreceptor tyrosine-based activation motifs 
(ITAMs) on CD3, subsequently recruiting Zeta-chain-associated protein kinase 70 
(Zap70). Zap70 will then be phosphorylated and activate the scaffolding protein linker of 
activated T cells (LAT) which will further recruit other adaptor proteins eventually 
leading to the activation of phosphatidylinositol 3-kinase (PI3K), and generation of 
inositol 1,4,5-trisphosphate (IP3), among other second messengers. IP3 will then diffuse 
through the cytosol and induce Ca2+ to be released from the endoplasmic reticulum. This 
complex series of events will prompt activation of several downstream transcription 
factors such as:  activation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), activator protein 1 (AP-1), nuclear factor of activated T-cells (NFAT), 
along with others leading to T cell differentiation, T cell proliferation and production of 
inflammatory cytokines generating a effector T cell response (48). 
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Figure 1.2 
 
Figure 1.2: TCR Signaling.  
Schematic outline of TCR Signaling as discussed in the text. Reproduced with permission 
from  (46). 
 
 
 
 
 
 
 
 
15 
 
1.5 Protein kinase AKT 
The serine/threonine-specific protein kinase AKT, also known as protein kinase B 
(PKB) is gaining recognition as the site of a major crossroad in numerous cellular 
signaling pathways involved in the regulation of vital cell functions such as 
differentiation, proliferation, glucose metabolism and survival. As such, dysfunctional 
AKT is observed in many pathological conditions, including cancer (49), autoimmune 
disease (50), neurodegenerative conditions (51) and muscle atrophy (52), making it an 
attractive pharmacological target in current drug discovery programs.  
AKT research can be traced back to 1977 when Staal et al. (53) reported the 
isolation and characterization of AKT8, a murine virus that caused a high incidence of 
spontaneous lymphoma. The viral oncogene was termed v-AKT and, later the cellular 
homolog was identified as c-AKT in 1991 (54). Additionally, two other groups looking 
for members of the protein kinase C (PKC) and protein kinase A (PKA) superfamilies, 
identified a gene that encodes a serine/threonine protein kinase which they named PKB 
(55, 56). c-AKT and PKB were later identified as the same protein. Further studies 
demonstrated the critical involvement of AKT in growth factor signaling and 
oncogenesis. In 1995, it was reported that the lipid kinase phosphatidylinositol 3-kinase 
(PI3K) is directly upstream of AKT (57, 58) thus establishing a linkage of the PI3K-AKT 
pathway to metabolic functions such as protein and lipid synthesis, carbohydrate 
metabolism and transcription. As the field evolved, a new perspective on the role of AKT 
in growth, survival and metabolism became established and, with it, the foundation for 
the current compelling interest in the molecular regulation of AKT activity. 
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1.5.1 Protein structure of AKT 
AKT belongs to the cAMP-dependent protein kinase A/protein kinase G/protein 
kinase C (AGC) superfamily of protein kinases. Each AGC member exhibits similar 
enzymatic function and structural homology within their catalytic domains (59). Three 
different AKT genes have been identified in mammalian cells: AKT1/PKBα, 
AKT2/PKBβ and AKT3/PKBγ (55, 60-64). Although AKTs are expressed in all 
eukaryotes, the specific isoforms and level of expression varies depending on the tissue 
type. AKT1 is the dominant isoform in the majority of tissues and is critical during 
embryonic development (65-67). AKT2 is expressed mostly in insulin-responsive tissues, 
has non-redundant functions in glucose homeostasis (60), and AKT3 is restricted to testis 
and brain and is required for postnatal brain development (62-64).  
The three isoforms of AKT share a high degree of amino acid identity (~85%) and 
a common structural pattern that includes an amino terminal pleckstrin homology (PH) 
domain, a central kinase domain and a carboxyl-terminal regulatory domain with a 
hydrophobic motif (HM) (Figure 1.3). The PH domain is a protein module of 
approximately 120 amino acids best known for its ability to bind to cell membrane 
phosphoinositides. The AKT PH domain preferentially recognizes phosphatidylinositol-
3,4,5-triphosphate (PtdIns (3,4,5)P3) and, with  three fold lower affinity, PtdIns (3,4)P2 
(68, 69). Unlike PtdIns (4,5)P2 and PtdIns-4P, which are constitutively produced in cells, 
PtdIns (3,4,5)P3 and PtdIns (3,4)P2 are detected only in stimulated cells (70) thus 
providing an additional mechanism to regulate the recruitment of proteins such as AKT 
to the membrane. Next to the PH domain, the kinase domain shares a high similarity with 
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other AGC kinases and contains the catalytic function of AKT that exhibits a preference 
to phosphorylate the canonical consensus sequence RXRXX(S/T) (71). It contains the 
regulatory threonine 308 (T308) of which phosphorylation is required for AKT 
activation. AKT possesses a carboxyl-terminal regulatory domain characteristic of the 
AGC kinase family with an FXX(F/Y)(S/T)(Y/F) hydrophobic motif. This sequence 
contains serine 473 (S473), the second regulatory residue of which phosphorylation is 
necessary for full activation of the kinase. Together these regions make up a protein of 
approximately 56 kDa (72). 
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Figure 1.3 
 
Figure 1.3: Structure of AKT 
(A). Depicted is the structure of AKT1. AKT consists of three domains: the PH domain, 
the kinase domain and the COOH-terminal regulatory domain with a hydrophobic motif 
(HM). The kinase domain contains T308, one of two residues that need to be 
phosphorylated in order for AKT to become active. The second residue, S473, is located 
in the hydrophobic motif of AKT. Reproduced with permission from (6). 
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1.5.2 Activation of AKT 
Activation of AKT is a multi-step process that requires the receptor-ligand 
dependent activation of PI3K. PI3K is the lipid regulator that phosphorylates PtdIns 
(4,5)P2 and, with lower efficiency, PtdIns 4P,  at the 3’-OH position of the inositol ring to 
produce PtdIns (3,4,5)P3 and PtdIns (3,4)P2, respectively (Figure 1.4). In the initial step 
of its sequential activation, AKT translocates to the cell membrane through the PH-
mediated binding to PtdIns (3,4,5)P3. This binding generates a conformational change in 
AKT that exposes the two regulatory phosphorylation sites, T308 and S473. The fact that 
PH domains of Phosphoinositide-Dependent Kinase-1 (PDK1) and AKT share their high 
affinity for PtdIns (3,4,5)P3 favors their physical close proximity and enhances the 
efficiency of the PDK1-mediated phosphorylation of T308 in AKT. Phosphorylation of 
T308 only partially activates AKT and it is not yet clear whether it is a necessary prior 
event for phosphorylation of S473 (73). In order to reach full activation, AKT must be 
phosphorylated at both T308 and S473. The identity of the kinase responsible for 
phosphorylation of S473 remains controversial and several candidates have been 
suggested, including PDK1/2 and the mammalian target of rapamycin (mTOR) 
associated within the mTOR complex-2 (mTORC2) (74-78). mTOR, the kinase that is 
upstream of AKT as mTORC2, assembles within mTORC1, which is a direct, 
downstream AKT substrate. AKT-induced phosphorylation of other members in both 
mTORC1/2 complexes results in opposite effects on the AKT pathway. While phospho-
TSC1-2 sustains a positive feedback loop between mTORC2 and AKT (79), in some 
instances (i.e., the insulin receptor pathway) AKT phosphorylation of mTORC1/2 
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mediates the inhibitory feedback loop within the PI3K-AKT-mTORC1 axis (80). This complex 
interplay between mTOR and AKT, mediated by mTORC1 and mTORC2 coordinates 
and diverts the AKT signaling to specific sets of downstream pathways that will define 
the functional response of the cell. 
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Figure 1.4 
 
Figure 1.4: Regulation of AKT Activation 
Upon ligand binding to receptor tyrosine kinase (RTK), PI3K is recruited to the 
membrane where it phosphorylates its substrate PtdIns (4,5)P2 leading to the formation of 
PtdIns (3,4,5)P3. PtdIns (3,4,5)P3 induces AKT translocation to the membrane by binding 
to its PH domain and causing a conformational change that allows T308 and possibly 
S473 to become accessible to PDK1 and mTOR for phosphorylation. Once 
phosphorylated, full activation of AKT results in the regulation of multiple cellular 
events related to cell proliferation, growth and survival. AKT activity is negatively 
regulated by the action of PtdIns phosphatases PTEN and SHIP whose activity reduces 
the availability of the AKT-activating PtdIns (3,4,5)P3  Lastly, PP2A and PHLPP directly 
target AKT by dephosphorylating phospho-T308 and phospho-S473, respectively, thus 
reverting AKT to an inactive conformation. Reproduced with permission from  (6). 
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Overactivation of AKT can lead to the loss of proliferative and cell survival 
control that occurs in a wide array of solid tumors and hematopoetic malignancies. To 
maintain proper physiological function, AKT activity needs to be exquisitely balanced. 
Cells counterregulate AKT function via distinct mechanisms, including the degradation 
of PtdIns (3,4,5)P3 by inositol phosphatases. Phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) antagonizes PI3K activity and dephosphorylates the 3’-OH, 
generating PtdIns (4,5)P2 (81). The SH2-containing inositol polyphosphate 5-
phosphatase 1 (SHIP1) exhibits 5’-OH phosphatase activity to produce PtdIns (3,4)P2 
(82, 83). De-phosphorylation of PtdIns (3,4,5)P3 by PTEN and SHIP1 leads to the 
formation of inositol lipids whose binding affinity for AKT is significantly lowered. The 
PH domain-only protein PH-like domain family A member 3 (PHLDA3) competes with 
AKT for binding to both PtdIns (3,4,5)P3, and PtdIns (3,4)P2,  and the overexpression of 
PHLDA3 may block the localization of AKT to the membrane (84). In addition, AKT can 
be directly targeted by the action of phosphatases such as protein phosphatase 2 (PP2A) 
and the PH domain leucine-rich repeat protein phosphatase (PHLPP). While PP2A 
preferentially dephosphorylates AKT at T308 and, under certain conditions, also targets 
phospho-S473 (85-89), PHLPP dephosphorylates AKT specifically at S473 (Figure 1.4) 
(90-92).  
 
1.5.3 Pharmacological targeting of the AKT pathway 
The physiological relevance of AKT and the potential involvement of the AKT 
pathway in numerous pathological conditions have attracted major interest in AKT as a 
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pharmacological target. One such drug is the fungal metabolite rapamycin, which is 
currently approved for use in humans as an immunosuppressant to prevent rejection 
following organ transplantation. Rapamycin and its analogs (rapalogs), affect the AKT 
pathway by directly binding to the FKBP12 binding protein, which interacts 
preferentially with mTORC1 and blocks its downstream signaling activity. In some 
instances, inhibiting mTORC1 may result in pernicious effects by breaking the S6K-
dependent inhibitory feedback that restrains the PI3K-induced AKT activation (i.e. 
eliciting the opposite intended outcome) (93). Consequently, alternative therapeutic 
strategies to rapamycin have been proposed by combining the inhibition of mTOR 
function and AKT activation. In this context, the strong structural similarities between the 
catalytic domain of mTOR and the p110 subunit of PI3K (94) facilitate the dual 
inhibitory activity of new chemical compounds, distinct from rapalogs, that are currently 
being tested in clinical trials (clinicaltrial.gov ID number NCT00620594). The most 
common PI3K-specific inhibitors, the synthetic compound Ly294002 (95) and the fungal 
metabolite wortmannin (96), have been standard reagents in the experimental 
characterization of PI3K signaling, but their therapeutic use has been disregarded (97) 
and the attention has been shifted to a new generation of PI3K inhibitors that target the 
different isoforms of the regulatory p110 subunit. The potential therapeutic benefit of 
PtdIns analogs has also been debated. Nevertheless, despite their capacity to disrupt AKT 
activation, they may also generate specificity problems with respect to other PH domain-
containing proteins. In contrast, the direct inhibition of AKT is considered a very 
attractive but challenging therapeutic option, either alone or in combination with other 
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forms of therapy. Recently, several ATP-competitive inhibitors and novel allosteric 
inhibitors (PH domain-dependent small molecules) with selectivity for individual AKT 
isoforms are being actively characterized, some of which are in early phase of clinical 
trials or in clinical development (98-102).  
Active AKT profoundly affects cellular processes by phosphorylating numerous 
substrates. Consensus motif analyses reveal thousands of potential substrates for the 
enzymatic activity of AKT which can cause positive or negative regulation of the 
substrate. However, the consequences of phosphorylation by AKT on substrate function, 
localization or protein stability has only been characterized for approximately 50 
substrates to-date (103). 
 
1.6 The role of AKT in conventional T lymphocytes 
1.6.1 AKT in T cell development 
The thymic microenvironment directs the development, education and selection of 
T cells through the sequential integration of multiple extracellular cues that will 
ultimately generate the mature functional pool of circulating T cells. The first step in T 
cell development is the migration of early thymic progenitors (ETPs) from bone marrow 
to the thymus (104). Once in the thymus, ETPs transition through four stages as double 
negative (DN) T cells (DN1-4) before becoming double positive (DP) CD4+CD8+  T cells 
(105). The emergence of a mature T cell requires that the developing thymocytes pass 
through several pre-T cell receptor (pre-TCR)/TCR dependent selection events, the first 
of which takes place at the DN3 stage, followed by positive and negative selection during 
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the DP stage (106). Only DN3 thymocytes that express the newly created pre-TCRβ 
chain will survive – a process known as β-selection (107, 108). During the subsequent 
DP stage, additional positive and negative selection occurs in which phenotypic allelic 
exclusion at the TCRα locus is regulated and selectivity against T cells that are specific 
for self-peptide/MHC-complexes occurs (106, 109, 110). Although widely studied, the 
complete picture of signaling events and molecular mechanisms that control thymocyte 
differentiation is not well characterized. Experimental evidence suggests that AKT is 
essential during the transition from DN to DP, β-selection, allelic exclusion, and the 
subsequent proliferation that follows DP transition, but the identification of specific 
pathways in which AKT is involved is still the focus of very active research (111-116). A 
better understanding of the molecular events that control thymocyte development and T 
cell maturation will likely shed light upon the etiology and onset of a plethora of T cell-
related pathologies, including autoimmune diseases and malignant transformations. 
1.6.2 AKT in peripheral CD4+ effector T cell differentiation 
AKT signaling is involved in the peripheral differentiation of distinct effector TH 
cell subsets. Arimura et al. (117) found that the expression of a constitutively active form 
of AKT induced TH1 differentiation in C57BL/6 mice; however, AKT promoted TH2 
differentiation in BALB/C mice. Conversely, Kane et al. (118) reported that CD28-
induced AKT up-regulated the TH1 cytokines IL-2 and IFN-γ but not TH2 cytokines in 
BALB/C mice. These discrepancies were reconciled by the findings of Lee et al. (119) 
who investigated mTORC2. These authors created mice with a conditional deletion of 
rictor on C57BL/6 background, an essential subunit in the mTORC2 complex, and 
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reported that both TH1 and TH2, but not TH17 differentiation, were impaired. 
Additionally, they found that complementation with constitutively active AKT rescued 
only TH1 differentiation in mTOR deficient mice, whereas activated PKC-θ restored TH2 
cells, implying that mTOR-dependent AKT plays a pivotal role in the development of the 
TH1 subset, but not TH2. AKT has been also reported to be crucial for the expression of 
TH17 cytokines in CCR6+ human memory T cells (120).  
1.6.3 AKT activation in conventional T cells 
The plethora of stimuli and pathways that regulate AKT function underlines its 
crucial role in T cells. One of the first events was documented by Reif et al. (121), who 
showed that the addition of IL-2 to a human T cell line lead to stimulation of AKT in a 
PI3K-dependent fashion. Later, Lafont et al. (122) reported that TCR ligation, like IL-2 
ligation, also promoted a sustained, PI3K-dependent activation of AKT that lasts several 
hours (122). Co-stimulation through the CD28 receptor is required for optimal TCR-
dependent naïve T cell activation, cytokine production, cell survival and proliferation 
(123). Parry et al. (124) reported that upon CD28 co-stimulation, TCR-induced PI3K-
dependent AKT activation increased substantially in primary human T cells. Upon 
activation, AKT integrates and relays multiple pathways that dictate downstream events 
responsible for defining the outcome of the T cell function and fate. Phosphorylation of 
downstream substrates of AKT leads to activation or deactivation of a myriad of 
regulatory events in T cells. Among them, glycogen synthase kinase 3 (GSK-3) 
modulates the synthesis of glycogen in lymphocytes. GSK-3 is constitutively activated in 
the absence of growth factors and directly regulates nuclear factor of activated T-cells 
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(NFAT), a family of transcription factors involved in cytokine gene induction (125). 
NFAT activity is controlled by a nuclear import/export cycle governed by 
phosphorylation/de-phosphorylation (126). NFAT is directly phosphorylated by GSK-3, 
and the phosphorylation and inactivation of GSK-3 by AKT indirectly promotes NFAT-
dependent synthesis of pro-inflammatory cytokines in T cells (Figure 1.5). Similar to 
NFAT, the eukaryotic initiation factor 2 (eIF-2B) involved in the translational control of 
protein synthesis, is another substrate of GSK-3 that is rescued by AKT (127).  
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Figure 1.5 
 
Figure 1.5: Metabolic functions of AKT in conventional T cells 
Schematic outline of the downstream protein targets of AKT in conventional T cells as 
discussed in the text. Reproduced with permission from  (6). 
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AKT is also functionally linked with the transcription factor NF-κB (Figure 1.5), 
which is involved in T cell development, maturation and proliferation (128). Kane et al. 
(129) found that catalytically active AKT is necessary for the degradation of the NF-κB 
inhibitor IκB, although it is still controversial whether or not AKT alone is sufficient to 
induce NF-κB (130, 131) and whether or not IκB is a direct target of AKT (132, 133). 
Regardless of the precise mechanism, it is clear that the PI3K/AKT/NF-κB signaling axis 
is operative in activated T cells.  
 The FoxO forkhead family of transcription factors plays an important role in cell 
proliferation and differentiation and is another major target of AKT kinase (134). FoxO3 
is involved in cell cycle regulation and survival of T cells by inducing the IL-2-dependent 
expression of  the cell cycle inhibitor p27kip1 and the pro-apoptotic Bcl-2 family member 
Bim (135) (Figure 1.5). Like other transcription factors, FoxO activity is regulated by its 
nuclear localization, and its phosphorylation by AKT precludes its nuclear accumulation 
and activity (134, 136). In addition, AKT has been found to modulate the activity of 
another member of the Bcl-2 family, the pro-apoptotic BAD (137, 138). Upon 
phosphorylation, BAD dissociates from Bcl-2 and forms a very stable complex with 14-
3-3 protein, which allows the free Bcl-2 to associate with and inhibit the pro-apoptotic 
effect of Bax. AKT has been found to regulate cell survival through other pathways, 
including the NF-κB-dependent upregulation of Bcl-XL (139, 140), the activation of the 
transcription factor cyclic adenosine 3’,5’-monophosphate (cAMP)-responsive element 
binding protein (CREB) (141) and the direct inactivation of human caspase-9 (142).  
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With the caveat of the functional intricacies present in the interaction between 
AKT and both of the mTOR complexes, the observation that AKT can regulate mTOR 
activity opened the possibility that AKT can indirectly regulate protein translation 
(Figure 1.5) by either enhancing ribosomal-dependent protein synthesis through the 
activation of p70S6 kinase (143, 144) and through the mTOR-dependent inactivation of 
the translation repressor 4E-BP1. In contrast with the fundamental role of AKT in 
conventional T cell function, results from recent studies are consistent with the negative 
effect of AKT signaling in the development and suppressor function of Tregs. 
 
1.7 The role of AKT in regulatory T cell lymphocytes 
1.7.1 Inhibitory effect of AKT on Tregs 
In 2008 Sauer et al. (145) reported that the PI3K/AKT activity antagonized FoxP3 
expression in murine T cells. The involvement of the AKT pathway was further 
suggested in FoxP3 expression when a constitutively active AKT repressed the TGF-β 
induction of FoxP3 in a rapamycin-sensitive manner. In addition, the combined inhibition 
of both PI3K and mTOR greatly augmented FoxP3 induction in CD4+ T cells (145). Only 
a moderate direct inhibition of AKT was sufficient to increase FoxP3 expression in T 
cells, conveying that the blockage of AKT itself promoted FoxP3 expression rather than 
an upstream regulator. In a comparison of PI3K/mTOR inhibitor-induced cells to freshly 
isolated Treg cells, more than half of the transcripts specifically regulated in Treg cells 
were similarly regulated in FoxP3-induced cells via PI3K/mTOR inhibition, suggesting a 
substantial association between suppression of the PI3K/AKT pathway, and  de novo 
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expression of FoxP3 and Treg signature in mouse CD4+ T cells (145). The involvement 
of AKT in Treg development was further investigated by Haxhinasto (146), who reported 
that if FoxP3 expression was already established in T cells, the constitutive activation of 
AKT did not significantly decrease its expression. The authors also investigated the role 
of AKT in the development of nTregs and concluded that, like iTregs, activation of AKT 
significantly impaired thymic CD4+FoxP3+ nTreg development without altering positive 
selection of conventional CD4+ and CD8+ T cells. These results placed AKT at a nexus of 
signaling pathways with broad impact on the onset of Treg specification in thymus as 
well as on the differentiation of peripheral iTregs. 
In addition to the critical role of AKT on Treg development, recent reports 
established the negative impact of AKT on the suppressive function of human nTregs. 
Crellin et al. (147) investigated whether hyporesponsiveness and lack of cytokine 
production in Tregs compared to conventional T cells was the result of altered TCR 
signaling. The authors determined that CD4+CD25- T cells and CD4+CD25+ Tregs had 
equivalent levels of ERK1/2 and p38 phosphorylation upon TCR stimulation. However, 
CD4+CD25+ Treg cells displayed a consistent defect in phosphorylation of AKT at S473 
and T308 as well as reduced phosphorylation of the AKT substrates FoxO and S6, 
suggesting a specific blockade of the TCR-induced AKT pathway. Moreover, constitutive 
activation of AKT in nTregs led to increased proliferation and concomitant abrogated 
suppressive capacity, further supporting the requirement of a “silent” AKT to sustain 
Treg function. In addition, enhanced AKT activity in CD4+CD25+ nTreg cells did not 
suppress expression of FoxP3, CTLA-4 or CD25 which indicated that the loss of function 
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was not related to a phenotypic change (147). In conclusion, these seminal studies 
demonstrated the connection between biological function and the altered AKT signaling 
pathway in CD4+CD25+ nTreg cells. Unlike the AKT requirement in the conventional T 
cell effector response, AKT activation in Tregs significantly impairs their development 
and function. In an effort to understand the mechanisms that regulate the transition from 
conventional T cells to iTregs, our group has recently reported that the rewiring of the 
TCR pathway occurring during the iTreg differentiation also results in the specific 
blockade of TCR-dependent AKT activation and has elucidated some of the signaling 
events involved in this altered TCR signaling (148).  
 
1.7.2 The AKT network determines effector T cell sensitivity to Treg suppression 
The AKT pathway is not only critical for Treg development and function, but is 
also an essential determinant of effector T cell sensitivity to Treg cell-mediated 
suppression. In several murine models of spontaneous autoimmunity, such as the non-
obese diabetic (NOD) model of diabetes and the MRL/Mp model of systemic lupus 
erythematosus, Tregs function normally, but effector T cells are resistant to Treg-
mediated suppression (149-151). In addition, several strains of mice with altered T cell 
intracellular signaling were also refractory to iTreg activity (152, 153). It was not until 
King et al.’s publication (154) that a potential mechanistic explanation for the effector T 
cell insensitivity to Tregs was found in the hyperactivation of the PI3K–AKT pathway. 
Concrete evidence for a causal relationship between AKT and effector T cell resistance 
was confirmed in a recent study by Wehrens et al. (44) in human patients with juvenile 
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idiopathic arthritis (JIA). Tregs from synovial fluid and peripheral blood of patients with 
JIA were fully functional when compared to healthy controls; however, at the local site of 
autoimmune inflammation, proliferation and cytokine production of effector T cells was 
poorly controlled by Tregs. These T cells isolated from the site of inflammation had 
increased levels of active AKT, and the pharmacological inhibition of AKT kinase 
activity rendered them susceptible to Treg-mediated suppression. These findings 
demonstrate that not only a weak Treg niche, but also a dysfunctional effector population 
may account for the attenuated suppressor activity and loss of immune homeostasis (43). 
Further evidence for the importance of AKT in the effector T cell interplay with Tregs 
can be found in the homeostatic control of the maturation of Ag-primed cytotoxic T cell 
(CTL) precursors to become CTL effector cells by a mechanism that involves the 
inhibition of AKT, but not of STAT5 or Zap70 (155). 
1.8 The role of ion channels in T cells 
Ion channels are essential to proper T cell function as they are intimately involved 
in signal transduction, maintenance of membrane potential, cell motility and cell volume 
in T cells. Potassium ion channels (K+ channels) in T cells regulate the ability to maintain 
negative membrane potential during TCR induced Ca2+ flux and without them, Ca2+ flux 
would cease, resulting in a halt to TCR signaling. There are two common types of K+ 
channels that contribute significantly to the ionic environment in T cells: Kv1.3 and 
KCa3.1. Upon TCR ligation with MHC/antigen complex, IP3 diffuses through the cytosol 
and binds to its receptor (IP3R) on the endoplasmic reticulum. IP3R is a ligand gated Ca2+ 
channel that will release Ca2+ into the cytosol of the cell upon activation (156). Ca2+ 
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released from stores in the ER results in the opening of plasma membrane Ca2+ release-
activated Ca2+ (CRAC) ion channels, causing Ca2+ to influx into the cell from the external 
fluid (157, 158). The rise in intracellular Ca2+ activates calcineurin, which, in turn, 
activates NF-AT thus leading to the production of pro-inflammatory cytokines, and to T 
cell differentiation and proliferation (126). Negative membrane potential necessary for 
regulation of the magnitude of TCR-induced Ca2+ as well as Ca2+ influx (159) is 
maintained by K+ channels sensitive to changes in membrane potential (Kv1.3) or Ca2+ 
concentration (KCa3.1) (160). Activation of K+ ion channels stabilizes TCR-induced 
signaling by stabilizing Ca2+ influx (Figure 1.6) (161), thus making K+ ion channels 
attractive candidates for pharmacological intervention. Specific inhibitors of Kv1.3 
(Margatoxin) and KCa3.1(TRAM34) have been described in the literature (161). Kv1.3 
expression on specific T cell subsets has been linked to automimmune disease.   
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Figure 1.6  
   
Figure 1.6: TCR induced Ca2+ signaling and ion exchange.. 
Upon TCR engagement with MHC/antigen complex, phospholipase C gamma (PLC-γ) 
generates the second messenger IP3, inducing the release of Ca2+ from the endoplasmic 
reticulum. Increased cytosolic Ca2+ induces opening of CRAC channels in the plasma 
membrane, thus allowing a Ca2+ influx. Kv1.3 and KCa3.1 channels open allowing K+ 
efflux which contributes to the negative membrane potential that is the driving force for 
Ca2+ influx. Reproduced with permission from  (161). 
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An effector T cell response is generated upon antigen encounter. After the threat 
or pathogen has been eliminated in the body, a small percentage of the effector T cells 
differentiate into memory T cells that can respond very rapidly to another challenge. Two 
main types of memory CD4+ T cells are generated: central memory T cells (TCM) and 
effector memory T cells (TEM). TCM have little to no effector function, but can readily 
proliferate and differentiate to effector T cells when challenged with antigen. TEM are 
protective memory T cells that display characteristic sets of chemokine receptors and 
adhesion molecules that facilitate homing to inflamed tissues where they exert immediate 
effector function (162). Chronically activated TEM cells have been implicated in tissue 
damage associated with several autoimmune diseases, including MS (163), RA, asthma 
and type-I diabetes mellitus (164). Recent studies suggest that, when activated, TEM 
exhibit a specific change in K+ ion channel expression that does not occur in other T cells 
types (163, 165). Specific stimulation of either naïve or TCM cells results in only modest 
increases in expression of Kv1.3 channels, whereas KCa3.1 channel numbers were 
dramatically up-regulated upon stimulation of TEM cells. However, TEM activation leads 
to a significant increase of Kv1.3 channels without any change in levels of KCa3.1 (162). 
Up-regulation of specific K+ channels also coincides with increased proliferative ability 
of the TEM, thus it is reasonable to believe that targeting Kv1.3 in the diseases where TEM 
are provoking the pathology may be beneficial. These findings led several groups to 
investigate Kv1.3 channels in TEM as a therapeutic target for treating autoimmune 
diseases like MS (166), however investigation into Kv1.3 channel manipulation should 
include special consideration of Kv1.3 expression levels on Tregs as well due to the 
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importance of Kv1.3 in iTreg signaling mechanisms. Though inhibiting Kv1.3 on the 
pathogenic TEM has been suggested to control the disease severity, Kv1.3 inhibition on 
Tregs could lead to exacerbation of the disease. Therefore, understanding the role of the 
K+ ion channels in Tregs will be crucial to predicting and understanding the effects of 
this clinical trial on Treg function. 
 
1.9 IL-2 Signaling in T cells 
IL-2 is a cytokine primarily produced by CD4+ T cells following their activation 
by antigen that is widely considered to be a key cytokine in the T-cell dependent immune 
response (167, 168). IL-2 can promote T  cell growth, augment NK cell cytolytic activity, 
prompt differentiation of Tregs and mediate activation-induced cell death in T cells 
(167). The IL-2 receptor consists of three different chains α, β and γc (Figure 1.7a) (168). 
IL-2Rα chain (CD25) is expressed on activated T cells and binds to IL-2 alone with fairly 
low affinity. The IL-2Rβ (CD122) and the IL-2Rγ (common cytokine receptor γ chain) 
form a complex that binds IL-2 with intermediate affinity (169). When all three IL-2R 
chains are expressed in a cell the IL-2R becomes a high-affinity receptor and initiates 
strong IL-2R signaling.  Expression of the high-affinity IL-2R is critical for  T cells 
responses to low concentrations of IL-2 (170). CD25 expression is absent on naive and 
memory T cells but is induced after antigen activation. IL-2Rβ is constitutively expressed 
by NK, NKT, and memory CD8+ T cells but is also induced on naive T cells after antigen 
activation while γc is constitutively expressed by all lymphoid cells (170). Once the high-
affinity IL-2R is induced by antigen, IL-2R signaling upregulates the expression of CD25 
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in part through Stat5-dependent regulation of IL-2ra transcription (171).  This process 
represents a mechanism to maintain expression of high-affinity IL-2R and sustain IL-2 
signaling.  Upon ligation of IL-2 to its receptor, a series of signaling cascades are 
activated which include phosphorylation of signal transducer and activator of 
transcription 5 (STAT5) which translocates to the nucleus of the cell where it will 
regulate transcription; activation of PI3K which causes downstream activation of AKT; 
and phosphorylation of mitogen-activated protein kinase (MAPK) – all of which will lead 
to growth and survival of the T cell along with transcriptional regulation and effector T 
cell differentiation (Figure 1.7b). 
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Figure 1.7 
 
Figure 1.7: IL-2 Signaling. 
(a) IL-2R is composed of three subunits IL-2Rα (CD25), IL-2Rβ (CD122), and IL-2R γc, 
the combination of which creates a high affinity receptor. (b) Upon IL-2 binding to the 
receptor it will activate a signaling cascade leading to STAT5, PI3K and MAPK 
activation subsequently inducing growth, survival, transcriptional regulation and effector 
differentiation in the T cell. Reproduced with permission from  (168). 
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IL-2 is required, not only for iTreg and nTreg development, but maintenance as 
well (20).  Mice deficient in IL-2R develop a lethal autoimmune disease secondary to 
failed thymic development and impaired peripheral homeostasis of nTregs (172). The 
constitutive expression of the high-affinity IL-2R as detected by expression level of 
CD25 is used to characterize most Tregs.  IL-2 signaling in Treg cells differs from 
conventional T cells in that Treg cells essentially fail to activate the PI3K-AKT pathway 
because of  high PTEN protein expression (173, 174).  Indeed, though Tregs express 
high-affinity form of the IL-2R, increased levels of PTEN at least partially account for 
the failure of Tregs to undergo IL-2 dependent proliferation in vitro (174).  Additionally, 
IL-2 signaling through STAT5 activation has been found to promote FoxP3 expression in 
iTregs (175).  Understanding IL-2 signaling mechanisms will undoubtedly prove to be a 
crucial step in discerning critical signaling pathways in iTreg development.   
 
1.10 TGF-β Signaling in T cells 
Transforming growth factor-β (TGF-β) is a cytokine conserved across all 
leukocyte lineages, including lymphocytes, macrophages and dendritic cells, the 
production of which effects the differentiation, proliferation and activation of the immune 
cells (176, 177). TGF-β plays a pivotal role in regulating the immune response. Signaling 
through the TGF-β pathway will inhibit T and B cell proliferation and induce apoptosis 
as well as prevent TH1, TH2, or CTL differentiation. TGF-β can bind to both type I and II 
transmembrane serine/threonine kinase receptors (Figure 1.8) (178). However TGF-β 
signaling is a linear pathway initiated through TGF-βRII only, which will, in turn, 
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activate TGF-βRI leading to the phosphorylation of intracellular SMAD proteins. There 
are eight known SMAD proteins: receptor associated SMADs (R-SMADs1, 2, 3, 5, and 
8), one common SMAD (Co-SMAD4), and two inhibitory SMADs (I-SMAD6 and 7). R-
SMADs are sequestered in the cytoplasm in the absence of TGF-β signaling and are 
presented to TGF-βRI by scaffolding proteins such as SMAD anchor for receptor 
activation (SARA) (179), hepatic growth factor-regulated tyrosine kinase substrate (Hrs) 
(180), and disabled homolog 2 (Dab-2) (181). Once TGF-βRII activates TGF-βRI the R-
SMADs will become phosphorylated and will associate with Co-SMAD4. This R-
SMAD/Co-SMAD complex translocates into the nucleus where it will bind to the 
SMAD-binding element (SBE) in the genome inducing transcriptional regulation (182). It 
has recently been suggested that TGF-β plays an important role in the plasticity seen 
between iTreg and TH17 differentiation.  TH17 lineage has been identified as a subset 
that produce IL-17 and are generated in response to TGF-β and IL-23 or IL-6 signaling 
(183).  However, it has been found that TGF-β signaling along with IL-2 will induce the 
development of iTregs (20, 21, 184, 185). In more recent studies, it has been shown that 
SMAD3 binds to an enhancer of the FoxP3 gene, suggesting a possible role of TGF-β in 
iTreg differentiation (186, 187). Production of both inflammatory and anti-inflammatory 
cells through TGF-β signaling is believed to be accomplished through the influence of 
downstream cytokine signaling with divergent outcomes.  Tight regulation of the 
additional signaling pathways on TGF-β signaling allows the interplay between the two 
pathways generating reciprocal effects.  Conversely, SMAD-independent signaling may 
be regulating the differentiation of the proinflammatory TH17 cells whereas SMAD3 
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dependent signaling is regulating iTreg development. Nonetheless, the definitive role of 
TGF-β in the induction of iTregs and the cross-talk between TGF-β and other signaling 
pathways will be vital in elucidating its role in the development of iTregs.  
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Figure 1.8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: TGF-β Signaling 
TGF-β binding to TGF-βR leads to SMAD2 or SMAD3 activation/phosphorylation. Once 
phosphorylated, SMAD2/SMAD3 binds to the co-SMAD4 and translocates from the 
cytosol to the nucleus where it regulates transcription by binding to DNA. 
SMAD2/SMAD3 transcriptional regulation leads to differentiation, growth inhibition, 
deposition of extracellular matrix and apoptosis. Reproduced with permission from  
(178), Copyright Massachusetts Medical Society. 
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1.11 Overview of thesis 
 In this thesis, we will use a novel cell culture system that mimics human iTreg 
development to analyze the hypothesis that molecular reorganization of the TCR 
signaling network is critical for the differentiation of human peripheral CD4+ T cells into 
iTregs. In Chapter 2, we present the details of the materials and methods used throughout 
the thesis. Chapter 3 investigates the hypothesis that primary human CD4+ T cells will 
differentiate ex vivo into iTregs if cultured in the presence of anti-CD3, IL-2 and TGF-β. 
The overall goal is to generate a substantial number of human iTregs in order to use them 
as a therapeutic treatment for human disease and additionally to generate and expand 
stable iTregs to study the molecular mechanism that regulate their development. As iTreg 
development requires the presence of IL-2, TGF-β and CD3 stimulation, we expect to 
recapitulate this developmental milieu in culture. In Chapter 4, we will test the hypothesis 
that the differentiation of primary human T cells to suppressor iTregs involves the 
relocation of key proximal TCR signaling elements to the highly active IL-2R pathway. 
IL-2 is needed for iTreg development, however the signaling mechanisms behind this 
phenomenon and its cross talk to the TCR signaling pathway in human iTregs are 
unknown. Preliminary studies found that upon TCR activation there was no increase in 
phosphorylation of the Src-family kinase Lck suggesting a substantial rewiring of the 
TCR signaling pathway in iTregs. In Chapter 5 we will examine the reorganization of 
proximal TCR events during iTreg differentiation.  Previously, it had been shown that 
AKT is inactive in regulatory T cells, and that this blockage of AKT activity occurs for 
Treg function. However it had not been determined what is causing the blockade of AKT 
activity. We will address two hypotheses, the first one that there is differential regulation 
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of phosphatases and kinases leading to blockage of AKT activity in iTregs. Moreover, 
iTregs need TGF-β signaling to induce FoxP3 expression; however TGF-β signaling may 
lead to apoptosis in the T cells. We hypothesize that AKT overexpression results in AKT-
SMAD3 association, decreasing SMAD3’s ability to regulate transcription. We expect 
that AKT is regulating the balance of SMAD3 activity where it is need early during iTreg 
development, however if overly active can cause apoptosis in the cells. In Chapter 6 we 
will discuss the results found throughout this thesis and discuss potential future 
applications. This work provides a novel insight into the signaling mechanisms of iTreg 
development and has shed light on some potential targets for the use of iTregs as a 
therapy for the treatment of human disease.  
 
 
 
 
 
 
 
 
 
 
 
Copyright © Mary Catherine Reneer 2012 
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Chapter 2: MATERIALS AND METHODS 
 
2.1 Cell isolation, culture conditions, and sorting. 
The generation of human iTregs ex vivo has been described in detail in our papers 
elsewhere (148, 188). Briefly, human peripheral blood mononuclear cells (PBMC) from 
fresh buffy coats of healthy, anonymous blood donors (obtained from the Kentucky 
Blood Center, Lexington, KY) were isolated by centrifugation over a Ficoll-Hypaque 
gradient at 500 rcf for 30 min with no brake. CD4+ T cells were purified by negative 
selection (StemCell Technologies kit) and CD25- cells were further selected (Miltenyi) 
following manufacturer’s instructions. CD4+CD25- T cells were cultured at a 
concentration of 2-2.5x106/mL in RPMI-1640 supplemented with 2.06 mM Glutamax-I 
and 25 mM HEPES, 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL 
streptomycin, 50μM β-mercaptoethanol (2-ME), IL-2 (5 ng/mL, eBioscience), coated 
anti-CD3 antibody clone OKT3 (1 μg/mL, BioXCell) and TGFβ (2 ng/mL, Invitrogen). 
Cells were maintained in culture for 5-7 days with a change of medium on the third day. 
Naïve (CD45RA+CD25-), memory (CD45RA-CD25-) and iTreg (CD45RA-
CD25highCD127low) cells were sorted using a Cytomation MoFlo (Beckman Coulter) high 
speed sorter (University of Kentucky Cytometry Core Facility) and antibodies against 
CD45RA, CD127, CD25 (Miltenyi).  Cells were also analyzed directly from culture 
using antibodies against CD25, CD45RA, CD127, GITR, FoxP3 and CTLA4 (BD). The 
acquisition of Treg-like phenotype (high expression of CD25, FoxP3, CTLA4, GITR and 
low expression or absence of CD45RA and CD127) is concomitant with cells displaying 
a strong capacity to suppress the proliferation of CD4+ T cells (148) which we confirmed 
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in the present study. Between 20% and 35% of original CD4+CD25- T cells reproducibly 
develop to the iTreg phenotype.  For optimization of iTregs numbers the CD4+ T cells 
were cultured in AIMV (GIBCO), anti-CD3 (1µg/mL), IL-2 (5 ng/mL) and TGF-β (2 
ng/mL). 
2.2 Suppression Assay 
Purified CD4+CD25- cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE) (Molecular Probes) at a final concentration of 5μM in PBS with 0.1% BSA. 
CFSE labeled cells (105 per well) were cultured with CD3-CD28 beads (Inspector kit, 
Miltenyi) in the presence of sorted naïve, memory, effector T cells or iTregs (3x104 per 
well- ratio target CFSE labeled cells: effector cells of 3:1). After 5 days of co-culture, 
cells were harvested and the CFSE profile of the stained cells was analyzed by flow 
cytometry. The sequential dilution of CFSE fluorescence illustrates the number of cell 
divisions of target cells. 
 
2.3 Flow Cytometry 
All flow cytometry analysis was conducted on FACS Calibur (Becton Dickinson) 
using Cell Quest Pro Software (BD Biosceince) and further analyzed with FlowJo 
software (Tree Star, Inc.). For surface staining, 3X105 cells were washed in cold FACS 
buffer (PBS with 0.5% (w/v) bovine serum albumin (BSA) and 2 mM EDTA) and then 
incubated with saturating concentrations of appropriate antibodies for 15 minutes at 4oC. 
The cells were washed twice in cold FACS buffer before analysis. For intracellular 
staining, a FoxP3 staining kit was used (eBioscience) according to manufacturer’s 
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protocol. For experiments where the T cells were activated either with anti-CD3 or 
pervanadate, the cells were first rested for 6-7 hours at 4oC in RPMI without serum and 
then stimulated with anti-CD3 (0.5 mg/106 cells, BioXcell) and crosslinked with anti-
mouse IgG (1.2 mg/106 cells, Jackson) or 2 mM pervanadate for 3 min at 37oC. 
Antibodies used for flow cytometry:  CD45RA-FITC, CD127-APC, and CD25-PE 
(Miltenyi); FoxP3-APC and CTLA4-PE-Cy5 (BD); AKT-AF488 (Millipore); 
phosphorylated (P)-AKT S473, P-AKT T308, PTEN, P-PTEN, P-mTOR S2481, P-
mTOR S2448 and mTOR (Cell Signaling); SMAD3 and P-SMAD3 (Abcam) as per 
manufacturer instructions. For detection of unconjugated primary antibodies, a secondary 
anti-Rabbit-AF647 (Invitrogen) was used. For detection of intracellular cytokines, 
secretion of cytokines was block by monensin, a GolgiStop protein transport inhibitor 
(BD kit) for 4 hours and cells were activated with 2.5 ng/mL phorbol myristate acetate 
(PMA) (Fisher) and 250 ng/mL ionomyocin (MD Biomedical) for 2 hours at 37oC in an 
atmosphere containing 5% CO2 before the staining. The same procedure as above was 
then used to stain the cells for surface and intracellular marker. 
 
2.4 Western Blotting, immunopreciptiation and autoradiogram 
Cells were collected from culture, washed with PBS and then in ice cold Radio-
Immuno-Precipitation Assay (RIPA) buffer: 50mM Tris-HCl, pH 7.4; 150mM NaCl, 
0.1% SDS, 0.5% Na-Deoxycholate and 1% Triton X-100, supplemented with 1mM 
PMSF and Halt Protease inhibitor cocktail (Pierce). Lystaes were either examined by 
Western Blot or used to immunoprecipate proteins.  To examine the interaction between 
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AKT and SMAD3, T cells were collected, washed with PBS and then lysed for 
immunoprecipitation in cold immunoprecipitation (IP) lysis buffer: 50mM Tris-HCl, pH 
7.4; 150mM NaCl, 1% Nonidet P-40 and 0.5% n-dodecyl-b-D-maltoside. Lysis buffers 
were supplemented with 1mM PMSF and Halt protease inhibitor cocktail (Pierce). The 
lysates were pre-cleared using protein A/G PLUS agarose beads (Santa Cruz) then 
immunoprecipitated with either AKT antibody (Cell Signaling) or SMAD3 antibody 
(Abcam) and bound on agarose beads overnight at 4oC. After washing the pellet 5 times 
with IP lysis buffer, any bound AKT-SMAD3 was detected by Western blotting. For 
detection of Lck and CD122 interaction, lysates of 107 cells per condition were pre-
cleared with Protein A/G agarose beads (Santa Cruz). Lck was immunoprecipitated from 
lysates by incubation for 2 h at 4 ºC in Protein-A/G agarose beads precoated with either 
anti-Lck antibody (Santa Cruz) or isotype-matched IgG control. After 5 washes with IP 
lysis buffer, beads were resuspended in SDS-PAGE sample buffer, boiled for 3 min and 
analyzed by Western blot. Proteins from whole cell lysates or from immunoprecipitates 
were resolved on 10% or 12% gels by SDS-PAGE and transferred to polyvinylidene 
fluoride (PVDF) membrane, blocked for 1 hour in 2% FBS in TTBS at 37 ºC and 
incubated overnight in primary antibody (1 μg/mL or the concentration recommended by 
manufacturer) at 4ºC. Membranes were washed and incubated with horseradish 
peroxidase-conjugated secondary antibody for 30 min. at room temperature. Labeled 
proteins were visualized by chemiluminescence (Pierce ECL Western blotting substrate, 
Thermo Scientific). Western blots were analyzed with the following antibodies: anti-P-
Tyr (clone PY99), anti-Lck (clone 3A5), anti-Zap70, anti-LAT, anti-AKT, anti-ERK 1/2, 
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anti-CD122 (IL2-R β subunit), anti-Grb-2 and anti-GAPDH-HRP (Santa Cruz); anti-P-
Src (Y416); anti-Zap70 and anti-P-Zap70 (Y493); anti-STAT5 and anti-P-STAT5 
(Y694); anti-P-LAT (Y191); anti-P-AKT (Ser473); anti-P-ERK 1/2 (Thr202/Tyr204), 
anti-AKT, anti-Plcγ, anti-P-PTEN, anti-PTEN, and anti-mTOR (Cell Signaling). Kv1.3 
antibody (APC-002) was purchased from Alomone labs. For detection of unconjugated 
primary antibodies, a secondary anti-rabbit-HRP and/or an anti-mouse-HRP (Jackson) 
were used. Densitometric analysis with the ImageQuant v.5.1 software (Molecular 
Dynamics) was used to quantify the intensity of labeling. Pixel densities for each band 
were normalized within the same experiment and autoradiography exposure in order to 
reduce inherent variability of experiments and ECL exposure times. 
 
2.5 Ca2+ influx in T cells 
 Human CD4+ T cells were obtained from iTreg polarizing culture (anti-CD3, IL-
2, TFG-β) and washed with PBS. The cells were then stained with 1 μl/mL of 10 X 106 
cells Indo-1 dye (Invitrogen), which is a dye that will fluoresce at two different 
wavelengths depending on whether (400nm) or not (475 nm) it is bound to Ca2+, and 
incubated for 30 minutes at 37oC. Indo-1 stained cells were washed and then were treated 
with antibody against CD25 (Miltenyi), CD45RA (Miltenyi) and either biotinylated-CD3 
(Miltenyi) alone or biotinylated-CD3 clone OKT3 and biotinylated-CD28 clone CD28.2 
(Miltenyi) on ice for 15 min. After incubation with antibodies the cells were washed with 
PBS and treated with RPMI containing either 60 nM Margatoxin (Kv1.3 inhibitor) 
(Sigma), 60 nM TRAM34 (KCa3.1 inhibitor) (ENZO), or media alone at 37oC degrees in 
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the presence of 5% CO2.   Cells were washed and resuspended in hank’s balances salt 
solution (HBSS) (GIBCO). A baseline reading of Ca2+ flux was obtained by flow 
cytometer. Immediately following the addition of 5 mg/mL avidin (Invitrogen) to induce 
TCR signaling by crosslinking biotinylated antibodies, Ca2+ influx was measured again 
by reading both Indo-1 wavelengths for 5 minutes in a flow cytometer (Figure 2.1). T cell 
populations were distinguished by their expression of CD25 and CD45RA, naïve cells by 
their expression of CD45RA+CD25- and iTregs cells by their expression of CD45RA-
CD25Hi. The Ca2+ flux demonstrated in this dissertation is due to extracellular Ca2+ added 
to samples. Analysis of data was determined by the percentage inhibition, Ca2+ flux peak 
values were calculated for each population in RPMI only and set equal to 100 percent. 
Ca2+ flux peak values in the presence of Margatoxin or TRAM34 were subtracted from 
Ca2+ flux peak values in the presence of RPMI or DMF only. This difference was labeled 
as the percentage inhibition. 
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Figure 2.1 
 
 
 
Figure 2.1: Measuring Ca2+ influx  
Experimental procedure for measuring TCR-induced Ca2+ flux. Primary human CD4+ T 
cells were cultured for 5-6 days in iTreg polarizing media (anti-CD3, IL-2 and TGF-β), 
stained with Indo-1 AM calcium dye and incubated for 30 min at 37oC. Indo-1 loaded 
cells were washed and then labeled with biotinylated anti-CD3, biotinylated CD28, CD25 
and CD45RA. Baseline readings were taken for 30 seconds and avidin (5 mg/mL) was 
added to induce CD3 and CD28 crosslinking. Samples were then read for 5 minutes. 
Indo-1 dye fluoresced at different wavelengths when bound or unbound to Ca2+ thus 
allowing for investigation of intracellular Ca2+ levels within each T cell population. 
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2.6 Electrophysiology 
We used the automated IonWorks HT high-throughput patch-clamping system 
(Essen Instruments, Ann Arbor, MI) as a screening platform to determine Kv1.3 activity 
profiles in different T cell subsets and culture conditions. We used 100 mM K+-D-
gluconic acid, 50 mM KCl, 3mM MgCl2 and 5mM EGTA pH 7.3 as intracellular 
recording solution in the high-throughput patch-clamping screening. We followed the 
protocols and conditions as detailed elsewhere (189). Briefly, isolated lymphocytes in 
suspension (5 × 105 / mL) were dispensed into a 384-well patch-plate. The bottom of each 
well contained a micropore with a diameter of 1.6-1.8 μm allowing a single lymphocyte 
to be suctioned and positioned over the hole in each well. After electrical access to the 
cytoplasm was obtained, a depolarizing voltage step function from -80 to +40 mV was 
applied across the cell membrane. This depolarization opened voltage-gated ion channels, 
and the resulting whole-cell current through the plasma membrane was recorded. While 
the same cell was still attached, a specific blocker of Kv1.3 channels was added to each 
microwell. A second depolarizing step was applied to the cell, and the resulting whole-
cell current was recorded. The Kv1.3-specific current was defined as the difference 
between the pre-blocker and post-blocker electrical currents (Figure 2.2).  
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Figure 2.2A-C 
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Figure 2.2: High-throughput method for measuring Kv1.3 ion channel activity 
(A) Isolated lymphocytes in suspension (5 × 105 mL) were dispensed into a 384-well 
patch-plate. The bottom of each well contained a micropore with a diameter of 1.6-1.8 
μm allowing a single lymphocyte to be suctioned and positioned over the hole in each 
well. (B) After electrical access to the cytoplasm was obtained, a depolarizing voltage 
step function from -80 to +40 mV was applied across the cell membrane. This 
depolarization opened voltage-gated ion channels, and the resulting whole-cell current 
through the plasma membrane was recorded. (C) While the same cell was still attached, a 
specific blocker of Kv1.3 channels was added to each microwell. A second depolarizing 
step was applied to the cell, and the resulting whole-cell current was recorded. The 
Kv1.3-specific current was defined as the difference between the (B) pre-blocker and (C) 
post-blocker electrical currents. High-throughput patch clamp assay afforded us the 
ability to read the activity of Kv1.3 ion channels within 100s of lymphocytes 
simultaneously. Figure modified from (189).  
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2.7 Gene Expression 
Transcription of the AKT, PTEN, mTOR, and SMAD3 genes was quantified from 
CD25- T cells, effector T cells, and iTregs. FOXP3 (as a positive control) and GAPDH 
(housekeeping gene) were assessed as control. Total RNA was extracted from 5-7 X 106 
sorted cells. cDNA was obtained by reverse transcription and used as a template in a 
microarray analysis with the Affymetrix GeneChip System (Human Genome U133 Plus 
2.0 Array microchip) at the UK Microarray Facility. Results represent the comparative 
mean value of triplicates from three different donors relative to CD25- samples; bars 
represent the experimental range of the triplicates. Pertinent results were validated with 
real-time PCR. 
 
2.8 Immunofluorescence Microscopy 
 Cells were first rested for 6-7 hours on ice and then stimulated with anti-CD3 (0.5 
mg/106 cells, BioXcell) crosslinked with anti-mouse IgG-Rhodamine Red-X (1.2 mg/106 
cells, Invitrogen) for 3 min at 37oC. Cells were washed in PBS and fixed in 3.7% 
paraformaldehyde in PBS, washed in PBS, permeabilized for 2 minutes in PBS 
containing 0.5% TritonX-100, then washed in PBS and incubated in blocking solution 
(PBS 5% BSA with goat serum) for 1 hour. Cells were then washed in PBS and 
incubated with anti-AKT-AF488 (Millipore). Cells were washed 3 times in PBS, 
cytospinned for 3 minutes at 800RPM low acceleration on a Shandon Cytospin 4 
(Thermo Electron Corporation) to flatten cells on slides, and then coverslips were 
mounted onto slides using ProLong Gold Antifade reagent containing DAPI (Invitrogen). 
Appropriate controls were conducted to demonstrate the specificity of both primary and 
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secondary antibody labeling under all conditions. Deconvolution microscopy was 
conducted using a Carl Zeiss Imager.Z1 microscope and AxioVision Rel 4.8 software 
(Carl Zeiss Worldwide). A Z-series of focal planes were digitally imaged and 
deconvolved with the AxioVision constrained iterative algorithm (190). The process 
removes out-of-focus light and reassigns it to its point of origin to generate high 
resolution images. Multiple images containing several cells were collected and 
representative cells are shown. All images were digitally processed for presentation using 
ImageJ (191). Images shown are deconvolved and represent single Z-sections. For 
quantification of images, the colocalization highlighter plugin from ImageJ was used to 
determine the colocalization of AKT-CD3 (Institut Jacques Monod, Service Imagerie, 
Paris). AKT-CD3 colocalization was considered to be membrane bound AKT. 
Membrane-bound AKT was expressed as a percentage of total AKT from each cell. To 
examine the interaction between AKT and SMAD3, cells were collected from culture and 
then washed with PBS, following the same protocol as above for fixation and 
permeabiliztion. The cells were stained using primary antibodies against anti-AKT-
AF488 (Millipore) and anti-SMAD3 (abcam). For detection of unconjugated primary 
antibodies, a secondary anti-Rabbit-AF647 (Invitrogen) was used. The cells were then 
imaged using the same deconvolution steps as above.  
2.9 Transfections and Luciferase reporter assays 
 All transfections were performed using the AMAXA nucleofector system 
(LONZA) following the manufacturer’s instructions for stimulated human T cells 
program T-020 for conventional T cells and T-002 for iTregs. Cells were washed with 
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PBS and then transfected using 5 μg of pGL3 Basic (CAGA)12 MLP Luciferase 
(graciously donated by Dr. Ten Dijke (192)). Values were normalized with the renilla 
luciferase activity expressed from pGLRP (graciously provided by Dr. Michael Kilgore, 
University of Kentucky). Cells were collected after 24 hours in culture and luciferase 
activity was measured using Dual-Luciferase reporter system (Promega) and Lumat LB 
9507 luminometer (Berthold Technologies). Relative luciferase units are luciferase 
intensity/renilla intensity for each cell type. Luciferase values shown are representative of 
transfection experiments performed in triplicate in at least three independent experiments 
with different donors. 
 
2.10 Lipid Raft Isolation 
 Purified T cells were subjected to a 5-80% sucrose gradient centrifugation. 
Briefly, T cells were resuspended in MNE buffer (25mM MES (Sigma), 5mM EDTA 
(BioExpress), 0.15M NaCl (Sigma) and in ddH2O) and incubated on ice for 15-30 min. 
The cells were then lysed using a cold dounce homogenizer with lysis buffer (MNE, 
Triton X-100 (Fisher) and Halt protease inhibitor cocktail (Pierce)). The lysate was 
mixed with 80% sucrose (Fisher) and a 30% sucrose layer was added on top slowly 
careful to not disturb the two layers in ultracentrifugation tubes (Beckman). Lastly, a 5% 
sucrose layer was added on top without disturbing the other layers. Ultracentrifugation 
was performed on the gradient spinning overnight at 35,000 rpm, 4oC with no brake using 
Beckman Optima LE-80K Ultracentrifuge with SW55T rotor. After centrifugation, layers 
of 200 μl fraction were taken, RIPA buffer was added to each sample and incubated for 
30 minutes on ice. 500 μl of methanol was then added to each fraction and vortexed. 
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After vortexing, 250 μl of chloroform was added and the samples were vortexed again. 
Lastly, 500 μl of ddH2O was added, samples were vortexed and then centrifuged for 5 
min at maximum speed. The supernatant was removed and the pellet containing protein 
precipitates was washed with methanol, vortexed and centrifuged for 8 min at max speed. 
The supernatant was then removed and the pellet was allowed to dry. Once dry, the pellet 
was resupsended in sample buffer and analyzed by Western blot analysis as described 
above.  
2.11 Statistical Analysis 
The Kruskal-Wallis ANOVA test was used to determine differences in peak 
currents of Kv1.3 among multiple groups. Statistical comparisons of current distributions 
between two samples were performed using the Kolmogorov-Smirnov test. Differences 
were considered significant when p values were <0.01. The Repeated Measures ANOVA 
with a Student Newman-Keuls multiple comparison post-hoc analysis was used to 
determine differences in protein expression among three different T cell subsets. 
Differences between conventional and Tregs were analyzed using a two-tailed, paired 
student’s t-test. Differences were considered significant when p<0.05. 
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Chapter 3: Differentiation of Human iTregs ex vivo 
3.1 Introduction 
 Numerous diseases are caused by the dysregulation of regulatory T cells (17). 
Hence, understanding the precise mechanisms involved in their development, activation 
and suppressor function could provide potential insight for therapeutic use. The 
population of regulatory T cells known as iTregs has recently been shown to be the more 
prevalent source of circulating Tregs (25). Key evidence for the peripheral generation of 
Tregs comes from Vukmanovic-Stejic et al. in which they found human Tregs to be a 
rapidly proliferating population compared with naïve or memory T cells. However these 
cells were short lived and underwent apoptosis at a relatively rapid rate compared to 
naïve or memory T cells (24, 25). They also found that the number and function of 
CD4+CD25+FoxP3+ Tregs are maintained in humans even after the age of 70 (23). Hence, 
nTregs, or expansion of these cells, cannot explain the lifelong existence of human Tregs, 
especially when thymic function is reduced after puberty in man and the number of Tregs 
does not decrease with age. Therefore, they suggest that the majority of peripheral Tregs 
are iTregs (24, 193). Although murine models of colitis (194), type I diabetes (42), RA 
and graft versus host disease (195) have shown that injecting Tregs to be a beneficial 
therapeutic, there are fundamental differences between mouse and human Treg biologies 
which need to be elucidated before their clinical use (188). The lack of sufficient number, 
purity, stability and homing specificity to therapeutic Tregs necessitates an experimental 
platform to optimize conditions for their ex vivo expansion (196).  
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 Therefore, our lab has generated a novel cell culture model that mimics in vivo 
human iTreg development. This innovative system allows for the differentiation and 
expansion of iTregs ex vivo from an individual donor after 5-6 days in culture, along with 
the ability to simultaneously compare iTregs to naïve, memory and effector T cell 
populations within the same donor. Using this experimental platform, we characterize the 
day-to-day kinetics of iTreg development and the phenotypical analysis of the cell 
surface and intracellular T cell markers expressed on human iTregs, investigate the iTreg 
suppressor capacity by suppression assay through cell contact and soluble factors, 
examine cytokine production and determine the extent of iTreg proliferation.  
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3.2 Results 
3.2.1 Experimental procedure and kinetics of iTreg development 
 In order to investigate the generation of human iTregs ex vivo, we obtained buffy 
coats from the Kentucky Blood Center from anonymous donors. PBMCs were isolated by 
centrifugation over a Ficoll-Hypaque gradient. The CD4+ T cells were then purified by 
negative selection and CD25- cells were further selected using magnet separation (Figure 
3.1). The CD4+CD25- T cells were cultured in iTreg polarizing media that contained anti-
CD3, IL-2 and TGF-β for 5-6 days. The iTregs were then purified using FACS. Figure 
3.1 illustrates the experimental procedure used to purify the iTreg population. Monitoring 
iTreg development overtime in our culture system found that at day 0 in culture, most the 
T cells are CD25-FoxP3-CTLA4- (Figure 3.2). After one day of culture, CD4+ T cells 
start to express low levels of CD25 and CTLA4, with a few of the cells expressing FoxP3 
(Figure 3.2). As cells progressively develop into iTregs they express higher levels of 
CD25, CTLA4 and FoxP3 until 20-35% of T cells have differentiated into iTregs 
expressing high levels of CD25, CTLA4, and FoxP3, and are CD45RA negative (Figure 
3.2) at the end of five days in culture. Additionally, we have been able to optimize on cell 
culture conditions to generate approximately 80% of the CD4+CD25- cells into iTregs 
(Figure 3.3). To do this we cultured our CD4+CD25- T cells in AIM V media, a 
proprietary serum free formulation, optimized for proliferation of T cells.  Therefore, this 
novel cell culture system enables the development of a substantial number of regulatory 
T cells. If otherwise noted, we will be using standard iTreg polarizing conditions along 
this dissertation.  
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Figure 3.1 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic of experimental procedure. 
PMBCs are separated out of human peripheral blood via gradient centrifugation before 
magnetic negative selection of CD4+CD25- T cells. After five to six days in culture, cells 
undergo FACS and are co-incubated with heterologous CFSE labeled target cells to 
measure suppressor activity. Reproduced with permission from (188). 
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Figure 3.2 
 
Figure 3.2: Kinetics of iTreg Development 
Purified human primary CD4+CD25- T cells are cultured in iTreg medium. An aliquot of 
cells is collected just after isolation (day 0) and at days 1, 3, 4, 5 of cell culture to monitor 
the progress of CD45RA, FoxP3, CTLA4 and CD25 markers. The iTreg profile 
corresponds to CD45RA-, FoxP3Hi, CTLA4Hi and CD25Hi (highlighted in the black in-
graph window). Reproduced with permission from (188). 
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Figure 3.3 
 
Figure 3.3: Optimizing iTreg polarization 
Purified human primary CD4+CD25- T cells are cultured in AIMV with anti-CD3, IL-2 
and TGF-β for 5-6 days. An aliquot of cells is collected just after 5-6 days of cell culture 
to monitor the progress of CD45RA, FoxP3, CTLA4 and CD25 markers.  iTregs make up 
about 80% of the cell culture.   
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3.2.2 iTregs originated from highly proliferating cells 
After determining the kinetics of iTreg development we wanted to investigate the 
proliferative capacity of the T cells differentiating into iTregs. We have previously 
determined that iTregs start to develop at approximately day three in our culture system. 
We set out to determine if these cells were being induced from the proliferative cells or 
non-proliferative cells in culture. To do this, we purified human primary CD4+CD25- T 
cells, stained them with CFSE, and then cultured them for 5-6 days in iTreg polarizing 
media with anti-CD3, IL-2 and TGF-β. After 5-6 days in culture, the cells were then 
analyzed by flow cytometry for the expression levels of CFSE. We found that T cells that 
differentiate into iTregs in our culture system are highly proliferative and undergo at least 
three or more cell divisions (96% of the cells divided) with a division index of 2.3 
compared to CD4+ T cells who have only divided 22% with a division index of 0.4 after 
5-6 days in iTreg polarizing culture (Figure 3.4) as seen by the decrease in CFSE upon 
each cell division. The division index represents the average number of cell divisions that 
a cell in the original population has undergone including the cells which never divided. 
These results indicate that during iTreg development, the T cells need to undergo a 
significant amount of proliferation before they can differentiate into iTregs.  
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Proliferation of iTregs 
Purified human primary CD4+CD25- T cells were stained with CFSE and then cultured 
for 5-6 days in iTreg polarizing media with anti-CD3, IL-2 and TGF-β. After 5-6 days in 
culture the cells were then analyzed by flow cytometry using antibodies against CD25, 
and CD45RA. Proliferation in the cells was analyzed by CFSE dye dilution. iTregs are 
generated from highly proliferative cells that underwent at least three or more cell 
divisions (96% of the cell divided) with a division index of 2.3 compared to CD4+ T cells 
which have only divided 22% with a division index of 0.4. Figure is representative of 
three independent donors. 
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3.2.3 Phenotypic Analysis of human iTregs 
 Having investigated the developmental kinetics of iTregs along with showing that 
the cells that differentiate into iTregs are highly proliferative, we next wanted to conduct 
a more detailed examination of the iTreg phenotype generated in our cell culture system. 
To do this we cultured our cells for 5-6 days and then analyzed the expression of a 
complete panel of cell surface and intracellular markers. Our iTregs express higher levels 
of FoxP3 and CTLA4 when compared to naïve, memory and effector T cells (Figure 3.5). 
Also, iTregs exhibit high levels of GITR, which is present on activated T cells and is 
highly abundant on regulatory T cells (197) (Figure 3.5). CD127, the IL-7 receptor alpha 
chain had little to no expression on iTregs compared to conventional T cells. CD127 is 
usually present on effector T cells upon activation and has been found to inversely 
correlate with FoxP3 (198) (Figure 3.5). Additionally we detected CD86 expression in a 
subset of iTregs compared to naïve, memory and effector T cells.  CD86 is the 
costimulatory molecule usually abundant on APC (Figure 3.6) that, upon ligation with its 
ligand, will initiate a signaling cascade necessary for T cell activation and survival (199).  
This expression of CD86 on iTregs is highly unique as it is not expressed on other T cell 
subsets; suggesting that iTregs could interact with other T cells through CD86.  In our 
system, human naïve cells exhibit high levels of CD31, also known as platelet endothelial 
cell adhesion molecule (PECAM-1). CD31 is a protein member in the immunoglobulin 
superfamily likely involved in the migration of T cells (200); however human iTregs do 
not express CD31 (Figure 3.6) indicating a change in the pattern of migration in vivo. The 
chemokine (c-c motif) receptor 2 (CCR2) and CCR1 are also present on iTregs like their 
effector T cell counterparts (Figure 3.6) implicating that iTregs can traffic to the site of 
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inflammation. It has been reported that tumor leukocyte infiltrates express CCR1 (201).  
Moreover, human iTregs express CD58 or lymphocyte function-associated antigen 3 
(LFA-3), which when bound to its ligand CD2 is thought to optimize immune recognition 
and T cell expansion (202) (Figure 3.6).  CD58/CD2 ligation has been shown to 
strengthen the interaction between the T cells (203), which may be critical for iTreg 
interaction with its target reinforcing the connection between the two cells thus allowing 
iTregs to suppress their target cell. Lastly, CD30, a marker of activated T cells (204) was 
present on iTregs and has been proposed to be involved in the regulatory function of 
Tregs in vivo (205). These data suggest that the iTregs generated in our cell culture 
system are not only numerous in quantity but also possess a phenotype consistent with 
regulatory T cells. 
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Figure 3.5  
 
Figure 3.5: Phenotype of iTregs 
Negatively selected human CD4+CD25- T cells were stimulated in vitro. Based on the 
expression of CD25 and CD45RA, four cell populations can be distinguished after 5-6 
days in culture: iTregs (CD25HiCD45RA-, blue) and effector (CD25MedCD45RA-, green), 
memory (CD25-CD45RA-, orange) and naïve (CD25-CD45RA+, red) T cells. The cell 
populations were then investigated for their expression of FoxP3, CTLA4, GITR and 
CD127. The iTreg population is CD25Hi, CD45RA-, FoxP3Hi, CTLA4Hi, GITR+ and 
CD127-/low.  
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Figure 3.6 
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Figure 3.6: Detailed Phenotype of iTregs 
Negatively selected human CD4+CD25- T cells were stimulated in vitro. Based on the 
expression of CD25 and CD45RA, four cell populations can be distinguished after 5-6 
days in culture: iTregs (CD25HiCD45RA-) and effector (CD25MedCD45RA-), memory 
(CD25-CD45RA-) and naïve (CD25-CD45RA+) T cells. The cell populations where then 
investigated for their expression of FoxP3, CTLA4, CD86, CD31, CCR2, CD58, CD30 
and CCR1. iTregs were found to express FoxP3, CTLA4, CD86, CCR1, CCR2, CD58, 
and CD30, but to be CD31 negative.  
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3.2.4 Suppressive Ability of human iTregs 
 The human iTregs generated in our system express markers that have been found 
to be present on Tregs. However in order to identify iTregs a true regulatory T cell we 
wanted to investigate their ability to suppress the activation of effector cells. To test this, 
we cultured CD4+ T cells that had been stained with carboxyfluorescein succinimidyl 
ester (CFSE- a dye that will progressively dilute and halve in fluorescence with every 
division of the cell) with either purified iTregs, naïve or memory T cells for 5 days. The 
CFSE labeled/target cells were cultured at a ratio of 3 targets cells per 1 effector 
(iTreg/naïve/memory). After 5 days in culture we then analyzed the dilution of CFSE 
within the effector/target cells indicating the amount of proliferation in the cells. We 
found that, in the presence of naïve or memory cells, approximately 45% of the CFSE 
target cells proliferated (Figure 3.7). However, when the target cells were cultured with 
human iTregs, the proliferation was dramatically decreased to less than 15% of the CFSE 
target cells (Figure 3.7), suggesting that iTregs arrest the proliferation of effector T cells. 
To investigate whether or not iTregs suppress through cell-to-cell contact or through 
soluble factors, we performed a Transwell suppression assay where the CFSE target cells 
and iTregs were separated by a 0.4 μm pore size membrane, thus preventing cell-to-cell 
contact. We determined that when the CFSE target cells were cultured at the same ratio 
as above with 3 target cells:1 iTreg, 61.8% of the CFSE target cells proliferated, 
suggesting that the mode of suppression may be through cell-to-cell contact (Figure 3.8). 
However, increasing the ratio of target cells to iTregs to 1:1 caused the proliferation of 
the CFSE target cells to decrease to about 37.6%. This effect was even more dramatic if 
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the ratio was changed to 1 CFSE target cell:3 iTregs (19.4%) implying that at higher 
quantities of cells human iTregs can suppress using soluble factors (Figure 3.8). Taken 
together these results indicated that human iTregs are in fact a suppressor T cell 
population which may utilize cell-to-cell contact and/or soluble factors to regulate 
effector T cell proliferation.  
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Figure 3.7 
 
 
Figure 3.7: Suppression Assay 
Purified CD4+ CFSE labeled effector cells (1 X 105/well) are cultured with Treg 
suppression inspector beads in the presence of sorted naïve, memory or iTreg cells (3 X 
104/well) at a ratio of 3 target/CFSE cell:1 Treg. After five days, cells were harvested and 
the CFSE profile of the stained cells was analyzed by flow cytometry. The presence of 
iTreg cells completely abolished the proliferation of CD4+ T cells. Numbers are 
indicative of percentage of CFSE-labeled cells that have undergone division. Figure is 
representative of three independent donors. Reproduced with permission from (188). 
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Figure 3.8 
 
Figure 3.8: Transwell Suppression Assay 
Purified CD4+ CFSE labeled effector cells (1 X 105/well) are cultured with Treg 
suppression inspector beads in the presence of sorted iTreg cells (3 X 104/well) at three 
different ratios of target/CFSE cells:Treg (3:1, 1:1 and 1:3) in Transwell plates. iTregs 
along with the inspector beads were plated below the Transwell and the CFSE labeled 
cells were plated in the Transwell well. After five days, cells were harvested and the 
CFSE profile of the stained cells was analyzed by flow cytometry. The presence of iTreg 
cells completely abolished the proliferation of CD4+ T cells. Numbers are indicative of 
percentage of CFSE-labeled cells that have undergone division. Figure is representative 
of three independent donors. 
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3.2.5 Human iTregs produce IL-10 
 Having found that iTregs were secreting soluble factors that may suppress the 
proliferation of effector T cells, we wanted to identify potential soluble factor(s) 
involved.  TGF-β and IL-10 are both anti-inflammatory cytokines that are produced by 
Tregs and have been identified to inhibit T cell proliferation (206). Due to the fact that 
recently it has been shown that TGF-β is more prevalent on the cell surface of Tregs 
rather than being a soluble factor released into the microenvironment (207), we decided 
that it may be more probable that iTregs were producing IL-10 as the soluble factor 
inhibiting the proliferation of effector T cells.  To determine the extent to which iTregs 
were producing IL-10 we induced iTregs in culture and then treated with monensin, a 
GogliStop protein transport inhibitor, in the absence (Figure 3.9A) or presence (Figure 
3.9B) of PMA and ionomycin for two hours. After two hours we analyzed the 
intracellular accumulation of IL-10 using flow cytometry. We found that iTregs in both 
the absence and presence of a strong activation with PMA and ionomycin were producing 
IL-10 (Figure 3.9), suggesting that IL-10 may be the soluble factor in iTregs contributing 
to the regulation of effector T cell proliferation. All of these data lead to us to our 
working model that the CD4+ T cells that differentiate into iTregs are highly proliferative 
cells that must undergo a substantial round of proliferation before developing into iTregs 
(Figure 3.10). Following proliferation, signaling network rewiring occurs that induces 
transformation of the T cells into iTregs (Figure 3.10). 
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Figure 3.9 
 
Figure 3.9: iTreg IL-10 production 
Purified human primary CD4+CD25- T cells are cultured for 5-6 days in iTreg polarizing 
media and then treated with monensin, a GogliStop protein transport inhibitor in the 
absence (A) or presence (B) of PMA and ionomycin for 2 hours. The treated T cells are 
then analyzed by flow cytometry using antibodies against CD25, CD45RA, FoxP3 and 
IL-10. The histogram represents increasing amounts of IL-10 expression in the different 
T cell populations (based on CD25, CD45RA and FoxP3 expression). iTregs produce the 
highest level of IL-10 with or without strong activation with PMA and ionomycin. Figure 
is representative of three independent donors. 
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Figure 3.10 
 
 
 
 
 
 
 
Figure 3.10: Model of iTreg development 
iTreg development may occur in two main steps. The CD4+ T cells first undergo a 
significant round of proliferation in culture. Once divided, the cells then undergo a 
rewiring of signaling networks which leads to differentiation of the T cells into iTregs. 
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3.3 Summary 
 In summary, primary human CD4+ T cells will differentiate ex vivo into iTregs if 
cultured in the presence of anti-CD3, IL-2 and TGF-β. We are able to generate relatively 
large amounts of iTregs (20-25% iTregs in culture). iTregs start to develop around day 
three in culture and have fully developed after five to six days in culture from a 
population of highly proliferative T cells that have undergone significant rounds of 
proliferation before differentiating into iTregs. We have also been able to optimize our 
cell culture system to generate the maximum about of iTregs possible.  Human iTregs 
produced in this manner do appear to exhibit phenotypic markers of regulatory T cells, as 
they express high levels of CD25, FoxP3, CTLA4, GITR, along with some other markers 
that are typically present on Tregs (CD86, CCR2, CCR1, CD58, and CD30). iTregs failed 
to express CD45RA, CD127 and CD31. iTregs suppress the proliferation of target 
effector T cells even at a low ratio of 3 effectors to 1 iTreg through cell-to-cell contact 
along with soluble factors, like IL-10, which are probably involved. The data in this 
chapter suggest that our cell culture system may be able to generate a sufficient quantity 
of iTregs to use them as a therapeutic option in treatment of human disease. Also, the 
development of this novel cell culture system to induce human iTregs gives us a near 
ideal experimental platform to study the signaling molecular mechanisms involved in 
their development.  
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Chapter 4: Proximal TCR Signaling in Human iTregs 
 
4.1 Introduction 
 The physiological relevance of Tregs in the control of the immune response 
emphasizes the importance of understanding the molecular mechanisms underlying their 
development and function. The intrinsic limitations of studying iTregs have prevented a 
comprehensive understanding of the differential signaling events that govern the 
development and function of Tregs. Sauer et al. described some of the signaling 
mechanisms in regulatory T cells when they found that the AKT/PI3K pathway inhibits 
FoxP3 expression in regulatory T cells (145). Moreover, constitutive activation of AKT 
in regulatory T cells leads to increased proliferation and concomitant abrogated 
suppressive capacity (147), further supporting the requirement for a “silent” AKT to 
sustain Treg function. We have taken advantage of our unique cell culture system 
outlined in Chapter 3 to obtain a better understanding of the signaling events that 
contribute to the altered proximal TCR-mediated activation of iTregs. We propose that 
differentiation from CD4+ T cells to iTregs involves the rewiring of the signaling network 
associated with TCR–dependent events upstream of the AKT pathway.  
 The TCR becomes activated in response to binding to a complementary 
MHC/peptide complex. Upon ligation, the TCR changes conformation allowing the 
ITAMs on CD3 to be exposed, and the Src-family kinase Lck to phosphorylate the 
ITAMs. Recent reports propose that a pool of pre-activated-Lck gains access to the 
ITAM sequences within the CD3/TCRζ complex exposed by the conformational changes 
82 
 
secondary to TCR engagement (208, 209). In this model, the critical priming step in the 
initiation of the TCR pathway would be the substrate accessibility (i.e. CD3 and TCRζ 
cytoplasmic tails) to the pool of available Lck, rather than Lck activation itself. Once Lck 
is recruited to the TCR complex, a subsequent kinase, Zap70, is recruited. Following 
recruitment, Zap70 will then be phosphorylated and activate the scaffolding protein LAT 
which will further recruit additional adaptor proteins, eventually leading to the activation 
of PI3K and generation of IP3 among other second messengers. PI3K activation directly 
leads to AKT activation while IP3 generation sparks a wave of signaling cascades that 
will induce Ca2+ influx into the T cell. Continued activation of the TCR signaling 
pathway through stimulation of the TCR is required for long-term T-cell activation and is 
dependent upon sustained Ca2+ influx. In order for Ca2+ influx and, thus, TCR signaling, 
to be sustained, an electrostatic imbalance between the intra/extracellular environments is 
maintained by K+ efflux through Kv1.3, KCa3.1 and other ion channels. The TCR 
signaling cascade is very rapid. Ligation with MHC/peptide complex leads to numerous 
downstream events inducing the activation, proliferation and differentiation of the T cell. 
We hypothesize that the phenomenon of “silent” AKT is also occurring in human iTregs 
and may account for a defect in upstream events. In this chapter, we examine the events 
upstream of AKT activation following TCR stimulation. This data will lead to a better 
understanding on how AKT activity is blocked in iTregs shedding light on the possible 
molecular rewiring occurring during iTreg development.  
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4.2 Results 
4.2.1 TCR-dependent signaling events in iTregs 
 To investigate the TCR signaling induced in human iTregs we cultured CD4+ T 
cells in iTreg polarizing conditions (anti-CD3, IL-2 and TGF-β) for 5-6 days, purified 
them using flow cytometry and analyzed the TCR signaling upon CD3 crosslinking. As 
expected, iTregs generated in our conditions acquired specific Treg signaling trademarks. 
Notably, iTregs exhibited a low activation of AKT in response to TCR engagement 
(Figure 4.1B). In contrast, remarkably effective ERK activation was evident (Figure 
4.1B) along with substantially increased pattern of phosphotyrosine in several, but not in 
all, proteins as compared to effector T cells (Figure 4.1A), indicating that the blockage of 
the AKT pathway in iTregs did not occur due to a general failure of the TCR signaling 
machinery. iTreg cells exhibited the highest levels of active Lck in mock-treated samples 
under normal resting conditions (2 hours on ice), as indicated by the intense 
phosphorylation of Lck at Y394 (Figure 4.1B). However, iTregs displayed a reduced 
capacity to increase Lck activation in response to TCR ligation possibly because of high 
basal Lck activity in rested cells. This decreased ability to activate Lck was not derived 
from a difference in total protein or gene expression of Lck in iTregs compared to 
effector T cells (Figure 4.1C). These data suggest that human iTregs exhibit the same 
inhibition of the AKT pathway as seen in other Treg populations; however this doesn’t 
appear to be caused by a total failure of TCR signaling. Additionally, our data indicates 
that Lck is not further activated in response to TCR signaling but is active in rested 
iTregs.  
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Figure 4.1 A 
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Figure 4.1B 
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Figure 4.1 C 
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Figure 4.1: TCR-dependent signaling in iTregs. 
(A) Sorted CD4+CD25-, effector and iTregs were rested for 2 hours on ice, activated (+) 
or not activated (-) by anti-CD3 and anti-mouse IgG cross-linking for 3 min, then 
subsequently lysed (5 X 105 cells) and analyzed by Western blotting for the presence of 
phosphotyrosines. The amount of phosphotyrosines was indicative of the level of TCR 
signaling activated in each cell type. (B) Sorted CD4+CD25- T cells, effector T cells and 
iTregs were rested for 2 h on ice and activated (+) or not activated (-) by anti-CD3 
crosslinking for 3 min. Lysates of 5 X 105 cells were analyzed by Western blot to detect 
activated (phosphorylated) forms and total protein expression of Lck/Fyn (anti-pY416-
Src recognizes both pY394-Lck and pY417-Fyn), AKT, LAT and ERK. GAPDH 
expression demonstrated equivalent loading. Protein band densities were quantified by 
densitometry. Ratio of phosphorylated:total protein was normalized to that of mock-
treated CD25- cells and depicted as mock-treated (empty bars) or CD3 crosslinked (black 
bars) cells. (C) Lysates from 5 X 105 cells were analyzed by Western blot to detect the 
pattern of expression of proteins involved in early events of TCR signaling. Protein band 
densities were quantified and normalized to that of CD25- cells as indicated below each 
blot. Transcription of the LCK gene was quantified from CD25- T cells, effector T cells 
and iTregs. FoxP3 (as a positive control) and GAPDH (housekeeping gene) were 
assessed as controls. Briefly, total RNA was extracted from 5 to 7 X 106 sorted cells. 
cDNA was obtained by reverse transcription and used as a template in a microarray 
analysis with the Affymetrix GeneChip System (Human Genome U133 Plus 2.0 Array 
microchip). The results represent the comparative mean value of triplicates from three 
different donors relative to CD25- samples; bars represent the experimental range of the 
triplicates. The results were validated with real-time PCR (not shown). Reproduced with 
permission from  (148). 
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4.2.2 Lck relocates to the highly active IL-2 receptor 
 One phenotypic attribute of iTregs is the high expression of CD25, the IL2-Rα 
subunit that associates with the IL2-Rβ (CD122) and the common γ (CD132) chains to 
form the high affinity IL2-R complex. In conjunction with the requirement for a constant 
supply of IL2, the enhanced expression of the high affinity IL2-R complex underscores 
the critical role that the IL2/IL2-R pathway plays in iTreg development (184, 210). In this 
context, the fact that Lck exhibited a similarly enhanced activity in iTregs when the TCR 
signaling machinery was not triggered suggests that an alternative pathway might activate 
Lck. In order to assess the potential involvement of the highly active IL2-R, we 
performed co-immunoprecipitation assays of Lck from effector T cells and iTreg lysates. 
Our results confirmed that the physical association between Lck and the IL2-Rβ subunit 
occurred only in iTregs (Figure 4.2A). In addition, Lck appears to be activated upon IL2-
R engagement in iTregs. Sorted iTreg cells rested for an additional period of time (6-7 
hours on ice) revealed the activation of TCR-dependent downstream events (as depicted 
in Figure 4.2B by the phosphorylation of LAT), though the actual level of activated Lck 
was essentially identical for TCR cross-linked and mock-activated cells. Conversely, a 
marked increase of Y416-phosphorylated Src was detected in iTreg cells treated with IL2 
that paralleled the IL2-R-induced phosphorylation of STAT5. In agreement with others 
(211, 212), these findings support the direct involvement of Lck in the IL2-R signal 
transduction pathway of iTregs (Figure 4.3). As we observed no differences in Lck 
expression between conventional T cells and iTregs (Figure 4.1C), these results are 
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consistent with the redistribution of Lck to the IL2-R cluster occurring during the 
development of iTregs. 
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Figure 4.2 
 
Figure 4.2: LCK responds to IL-2 in iTregs 
(A) Lysates from 107 effector T cells and iTregs which were induced in our optimization 
media were incubated with Lck antibody-loaded agarose beads or Ig-isotype control 
(IgC). Cell extracts and immunoprecipitates were analyzed by SDS-PAGE and Western 
blots using CD122 (IL-2-Rβ) and Lck antibodies. Quantification of co-
immunoprecipitates was determined by the relative ratio of IL-2-Rβ-bound to Lck and 
normalized to 1.0 in effector cells. (B) Sorted iTregs which were induced in our 
optimization media were rested for 6–7 h on ice and mock-activated, anti-CD3 
crosslinked for 3 minutes or IL-2 treated for 5 hours. Lysates of 5 X 105 cells were 
subjected to immunoblotting using the indicated antibodies. LAT expression verified 
equal loading. Quantification of protein expression was normalized on the basis of mock-
treated iTregs for each individual blot. Representative of three independent donors. 
Reproduced with permission from  (148). 
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Figure 4.3 
 
Figure 4.3: LCK relocates to the IL-2R in iTregs. 
Upon TCR engagement with MHC bound to peptide will lead to a series of signaling 
events conveying activation of the Src-family linked kinase Lck and Zap70 in effector T 
cells. Once these kinases are activated, subsequent downstream adaptor proteins are 
phosphorylated leading to the generation of second messengers which induce T cell 
differentiation, activation and proliferation. We have found that Lck relocates to the 
highly activated IL-2R complex in iTregs. Upon IL-2 binding to IL-2R, Lck is 
phosphorylated/activated, suggesting that Lck is rewired from the TCR to the IL-2R and 
is involved in IL-2 signaling.  
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4.2.3 Impaired LAT activation in iTregs  
 Because we have demonstrated a partial defect in the TCR signaling pathway of 
iTregs in proteins like Lck and AKT, we wanted to investigate additional members of the 
TCR pathway for changes in signaling profile. LAT is a scaffolding protein 
phosphorylated in response to TCR stimulation which couples antigen receptor activation 
to downstream signaling cascades (213) making it an attractive candidate for differential 
regulation in iTreg signaling.  We set out to examine where or not LAT became 
differently phosphorylated after TCR stimulation in Tregs compared to effector T cells. 
Purified human CD4+ T cells were cultured in iTreg polarizing media (anti-CD3, IL-2 
and TGF-β) for 5-6 days. Sorted iTreg and effector T cell populations were rested for 6-7 
hours on ice and then activated with anti-CD3 for TCR signaling or IL-2 for IL-2R 
signaling. STAT5 was phosphorylated in iTregs and effector T cells suggesting that IL-
2R signaling was activated. In agreement with what has been previously demonstrated by 
others (145), AKT was activated in effector T cells but was inactive in iTregs in response 
to CD3 crosslinking (Figure 4.4). LAT phosphorylation was partially impaired in iTregs 
when compared to effector T cells (Figure 4.4), implying that relocation of Lck to the IL-
2R could be affecting downstream signaling and activation of LAT. PLC-γ is recruited to 
the LAT complex upon TCR stimulation and relays information from the activated 
receptor to downstream signaling cascades through the production of second messengers 
which initiate the Ca2+ influx in T cells (214). We found that PLC-γ phosphorylation was 
substantially lower in iTregs compared to effector T cells (Figure 4.4), suggesting that 
downstream events such as Ca2+ flux may also be effected. 
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: LAT phosphorylation is impaired in iTregs 
Sorted effector and iTregs were rested for 6-7 hours on ice and mock-activated, anti-CD3 
crosslinked for 3 minutes or IL-2 treated for 5 hours. Lysates of 5 X 105 cells were 
subjected to immunoblotting using the indicated antibodies. The western blot was probed 
for the expression of P-STAT5, STAT5, P-AKT S473, P-LAT Y191, LAT, P-Zap70 
Y493, Zap70, P-PLCγ Y793 and GAPDH expression was used to verify equal loading. 
Representative of three independent donors.  
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4.2.4 Functional dissociation between Kv1.3 and TCR activation in iTregs. 
 It has been previously demonstrated that, in contrast to conventional CD4+ and 
CD8+ T cells, the activation of the K+ channel Kv1.3 is refractory to TCR stimulation in 
human nTregs (189). To explore whether iTregs displayed the same functional trait along 
with the acquisition of other regulatory/suppressor trademarks, we analyzed the response 
of Kv1.3 to TCR engagement among different T cell subsets. We first examined the 
protein and gene expression levels of Kv1.3 in iTregs compared to effector T cells and 
found that there was no significant difference between Kv1.3 protein and gene expression 
between the populations (Figure 4.5). We next investigated whether Kv1.3 was activated 
in response to TCR stimulation in iTregs. The Ca2+ flux was evaluated in iTregs upon 
TCR stimulation in the presence of or absence of the Kv1.3 inhibitor margatoxin. We 
determined that Ca2+ flux in response to TCR stimulation was inhibited in naïve T cells 
upon inhibition of the Kv1.3 channel, however iTreg Ca2+ flux remained relatively 
unaffected (Figure 4.6), indicating that TCR induced Ca2+ flux  was not dependent on 
Kv1.3 activity in human iTregs. 
To directly confirm that Kv1.3 was not activated by the TCR in iTregs we took 
advantage of an automated, high-throughput patch-clamp screening assay. High-
throughput patch-clamp assay is a revolutionary method to measure activity of ion 
channels within an entire population of cells (0-384 cells) simultaneously. Unlike 
conventional patch clamp techniques where ion channel activity is measured in one cell 
at a time, this method allowed us to visualize the complete distribution of ion channel 
activity within the entire population of cells at once. To perform this highly specialized 
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technique, cells were plated in a 384 well plate and the depolarization potential was read 
across the cell membrane in the presence or absence of Kv1.3 inhibitor. Figure 4.7A 
depicts a representative spread of Kv1.3 activity obtained in human effector T cells. The 
advantage of this method for measuring Kv1.3 activity is demonstrated in Figure 4.7A 
where a widespread distribution of Kv1.3 activity can be visualized within a single 
population. It is much more difficult to obtain such a complete cross-sectional picture of 
channel activity using traditional patch clamping techniques. Concise graphical 
representation of this distribution is illustrated in Figure 4.7B. Using this system to 
measure Kv1.3 activity in our T cell populations, we found that effector T cells had a 
substantial increase in Kv1.3 activity upon TCR stimulation when compared to CD25- T 
cells, indicating that Kv1.3 is active at the TCR and may be regulating the TCR induced 
Ca2+ flux in effector T cells (Figure 4.8).  However we identified a similar profile of 
weak Kv1.3 response upon TCR stimulation in both induced and natural Tregs (Figure 
4.8).  Combined with the observation of steady Kv1.3 mRNA and protein expression 
(Figure 4.5), these findings suggest the functional dissociation between TCR and Kv1.3 
activity is likely due to the remodeling of the TCR signaling network during iTreg 
differentiation. 
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Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Kv1.3 expression in iTregs 
Sorted CD4+CD25- T cells, effector T cells, and iTregs were analyzed by Western blot to 
compare the expression of Kv1.3. The double-banded pattern depicted in effector and 
iTreg Kv1.3 blots likely correspond to different glycosylation forms of Kv1.3 (215). 
Quantification of protein expression was normalized to the band density of CD25- cells. 
GAPDH levels demonstrate equal protein loading. Gene expression was determined as 
detailed in Figure 4.1C. Reproduced with permission from  (148). 
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Figure 4.6: TCR-induced Ca2+ flux is not affected in iTregs upon inhibiting Kv1.3 
Primary human CD4+ T cells were cultured for 5-6 days in iTreg polarizing media (anti-
CD3, IL-2 and TGF-β). Cells were then stained with Indo-1 AM calcium dye and 
incubated for 30 min at 37oC. Indo-1 treated cells were washed and further treated with 
60 nM Margatoxin, a Kv1.3 inhibitor, for 15 min at 37oC. The cells were then placed on 
ice and labeled with biotyinylated anti-CD3, CD25 and CD45RA. Baseline readings were 
taken for 30 seconds and the avidin (5 mg/mL) was added to induce CD3 crosslinking. 
The samples were then read for 5 minutes. T cell populations were distinguished by their 
expression of CD25 and CD45RA: naïve cells by their expression of CD45RA+CD25- 
and iTregs cells by their expression of CD45RA-CD25Hi. The Ca2+ flux shown comes 
from extracellular Ca2+ added to the samples. To determine percentage inhibition, Ca2+ 
flux peak values were calculated for each population in RPMI medium only and set equal 
to 100 percent. Ca2+ flux peak values in the presence of Margatoxin were subtracted from 
Ca2+ flux peak values in the presence of RPMI only. This difference is the percentage 
inhibition.  
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Figure 4.7A 
 
Figure 4.7B 
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Figure 4.7: High-throughput method for measuring Kv1.3 ion channel activity 
(A) Represented picture of Kv1.3 current obtained from 63 human primary effector T 
cells. The intensity of Kv1.3 activity varies from cell to cell, therefore measuring Kv1.3 
activity in a whole population of cells is critical to obtain a representative activity of the 
whole population. (B)  Representative graph of Kv1.3 activity in a population of effector 
T cells. Whiskers represent the 10th and 90th percentiles of experimental values; boxes are 
limited by the 25th and the 75th percentiles; the solid line is the median and the dark 
square represents the mean value.  
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Figure 4.8 
 
Figure 4.8: Kv1.3 activity in iTregs 
CD4+CD25- T cells and nTregs isolated from the same donor were cultured in iTreg 
polarizing medium (anti-CD3, IL-2 and TGF-β). After 6 days, CD4+CD25- T cells, 
effector T cells and iTregs were sorted and maintained for 60 h in serum-free AIMV 
medium with or without 0.15 mg/mL of soluble anti-CD3 antibody. Kv1.3 current in 
sorted cells and nTregs was measured with high-throughput patch-clamping screening. 
Experimental values represent the combined distribution of Kv1.3 measurements on 
individual cells isolated from three independent experiments. N = 255 CD4+CD25- cells; 
N = 186 effector cells; N = 88 nTregs; N = 129 iTregs. The distribution of Kv1.3 values 
is depicted in box plots with whiskers representing the 10th and 90th percentiles of 
experimental values; boxes are limited by the 25th and the 75th percentiles; solid lines are 
the medians, and dark squares represent the mean values. A two-sample Kolmogorov–
Smirnov test was used to compare paired distributions of Kv1.3 currents. ** represent 
p<0.01. Reproduced with permission from  (148). 
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4.2.5 Regulation of Kv1.3 function by the IL2-R pathway in iTregs. 
During the formation of the immune synapse, association between the Src-family 
tyrosine kinase Lck and Kv1.3 is necessary for the initiation of the TCR-mediated 
signaling (216-218), and has been reported in other, non-TCR-dependent T cell responses 
as well (219-221). Therefore, we explored whether a differential Lck activation in iTregs 
may occur simultaneously with the loss of control of Kv1.3 activity by the TCR. The 
functional incidence of Kv1.3 spatial redistribution has been documented in T cells (216-
221) and association of Kv1.3 with novel signaling partners and redistribution of Kv1.3 
to areas of increased signaling activity has recently been demonstrated.  In 2000, Levite 
et al. reported a physical and functional association of Kv1.3 with beta1 integrin in T 
cells, suggesting that integrin activation may be regulated by Kv1.3 (220). Additionally, 
it was shown that Kv1.3 localized with CD3 in T cells and appeared to be translocating to 
the immunological synapse formed between cytotoxic and target cells (216, 217) 
suggesting a physical relocation of Kv1.3 to areas of increased signaling activity.  Kv1.3 
channel compartmentalization in the immunological synapse has also been identified in 
systemic lupus erythematosus (218) suggests that Kv1.3 distribution can differ in 
pathologic states. To examine whether TCR-dissociated Kv1.3 becomes functionally 
linked to the highly active IL2-R complex, we performed high-throughput patch clamp 
analysis with sorted iTregs incubated with IL-2, IL-6 or IL-10. In contrast to the weak 
response observed upon TCR ligation (Figure 4.8), iTregs in culture with IL-2 sustain 
significantly larger magnitude of Kv1.3 currents compared to cells cultured with IL-6 or 
IL-10 (Figure 4.9). These results provide, to our knowledge, the first evidence of the 
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functional integration of Kv1.3 into the IL2-R pathway in human T cells. Moreover, the 
linkage of Kv1.3 to the highly Lck-activating IL2-R coincides with the functional 
uncoupling from TCR control (Figure 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Figure 4.9 
 
Figure 4.9: Kv1.3 responds to IL-2 in iTregs 
Sorted iTregs were cultured for 60 h in AIMV with or without 5 ng/mL of IL-2, IL-6 or 
IL-10. Depiction and measurement of Kv1.3 currents were performed as described in 
Figure 4.9. In iTregs Kv1.3 was found to be response to IL-2 stimulation. Profiles of 
Kv1.3 currents represent the combined values of two independent experiments. A two-
sample Kolmogorov–Smirnov test was used to compare paired distributions of Kv1.3 
currents. ** represent p<0.01. Reproduced with permission from  (148). 
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Figure 4.10 
 
Figure 4.10: Kv1.3 relocates to the IL-2R 
TCR engagement with MHC bound to peptide leads to a series of signaling events 
conveying activation of the Src-family linked kinase Lck and Zap70 in effector T cells. 
Once these kinases are activated, subsequent downstream adaptor proteins are 
phosphorylated leading to the generation of second messengers which activate the Kv1.3 
ion channel and induce T cell differentiation, activation and proliferation. In iTregs, Lck 
and Kv1.3 relocate to the highly activated IL-2R complex, which, upon IL-2 binding to 
IL-2R Lck, is phosphorylated/activated along with Kv1.3 suggesting that Lck and Kv1.3 
are functionally linked and are relocated from the TCR to the IL-2R for their involvement 
in IL-2 signaling.  
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4.2.6 Ca2+ flux in response to TCR stimulation remains intact in iTregs 
 Given our demonstration of a partial loss of TCR signaling in iTregs and 
relocation of Lck and Kv1.3 from the TCR to the highly active IL-2R, relocation of 
functionally linked Lck and Kv1.3 to the active IL-2R could have downstream effects on 
T cell Ca2+ influx. Therefore, we next investigated the status of TCR induced Ca2+ flux in 
iTregs. Using the Indo-1 dye to assess Ca2+ concentration, we demonstrated higher 
intracellular concentrations of Ca2+ in iTregs than effector T cells upon TCR stimulation 
(Figure 4.11). As Kv1.3 was unavailable to contribute to the electrochemical gradient 
normally permissive to Ca2+ influx, this data implicated an additional K+ ion channel 
linked to the TCR in iTregs.  
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Figure 4.11 
 
Figure 4.11: TCR-induced Ca2+ flux remains intact 
T cell populations were distinguished by expression of CD25 and CD45RA: effector T 
cells in orange, iTregs in green, memory in blue and naïve in red. The Ca2+ flux shown is 
from extracellular Ca2+ added to the samples. The iCa2+ index was normalized to the 
baseline reading before TCR signaling was induced for each population.  
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4.2.7 Regulatory switch of Kv1.3 and KCa3.1 in iTreg TCR signaling 
 Due to the fact that Ca2+ flux remains intact in iTregs, we explored the possibility 
that in iTregs another K+ ion channel was compensating for the lack of Kv1.3 at the TCR. 
A likely candidate for this role in iTregs, KCa3.1, is a K+ ion channel expressed on T 
cells that, like Kv1.3, is also activated in response to increases in intracellular Ca2+. We 
first examined the expression level of KCa3.1 and identified a significant increase in both 
KCa3.1 gene and protein expression in iTregs compared to effector and CD25- cells 
(Figure 4.12). Subsequent evaluation of KCa3.1 activity in response to TCR stimulation 
found that TCR-induced Ca2+ flux was substantially reduced compared to that of naïve 
cells upon treatment with a KCa3.1 inhibitor, TRAM34 (Figure 4.13). These data suggest 
a regulatory switch of K+ channel activity in iTregs that may constitute a key 
contributing factor in the signaling rewiring associated with the development of 
peripheral human iTregs and sheds new light upon the reciprocal cross-talk between TCR 
and IL2-R pathways. Confirmation of this finding by high-throughput patch clamp 
experiments is ongoing. 
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Figure 4.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: KCa3.1 expression in iTregs 
Sorted CD4+CD25- T cells, effector T cells, and iTregs 5 X 105cells were analyzed by 
Western blot and microarray to compare the expression of Kv1.3. Quantification of 
protein expression was normalized to the band density of CD25- cells. GAPDH levels 
demonstrate equal protein loading. Gene expression was determined as detailed in Figure 
4.1C. 
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Figure 4.13 
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Figure 4.13: TCR-induced Ca2+ flux is inhibited in iTregs by suppressing KCa3.1 
activity 
Primary human CD4+ T cells were obtained and cultured for 5-6 days in iTreg polarizing 
media (anti-CD3, IL-2 and TGF-β). We then stained the cells with Indo-1 AM calcium 
dye and incubated them from 30 min at 37oC. Indo-1 treated cells were washed and 
further treated with 60 nM TRAM34, a KCa3.1 inhibitor, for 15 min at 37oC. The cells 
were then placed on ice and labeled with biotinylated anti-CD3, CD25 and CD45RA. 
Baseline readings were taken for 30 seconds and then avidin (5 mg/mL) was added to 
induce CD3 crosslinking. Samples were then read for 5 minutes. The T cell populations 
were distinguished by expression of CD25 and CD45RA: naïve cells by their expression 
of CD45RA+CD25- and iTregs cells by their expression of CD45RA-CD25Hi. The Ca2+ 
flux shown is from extracellular Ca2+ added to the samples. To determine percentage 
inhibition, Ca2+ flux peak values were calculated for each population in DMF medium 
only and set equal to 100 percent. Ca2+ flux peak values in the presence of TRAM34 
were subtracted from Ca2+ flux peak values in the presence of RPMI only. This 
difference is the percentage inhibition.  
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4.3 Summary 
In contrast to effector T cells in which robust activation of the TCR signaling 
pathway occurs, human iTregs undergo partial activation of the TCR, as a consequence 
of a rewiring in the TCR signaling pathway. We have shown that iTregs have a blockage 
in the AKT pathway in response to the TCR consistent to what has previously been found 
by others in mouse and human Tregs. Additionally, we have identified higher Lck 
activity in rested iTregs compared to effector T cells.  However, upon TCR stimulation, 
Lck activation is not increased above resting levels in iTregs which could be caused by 
Lck redistribution from TCR to the IL-2R. Haughn et al. (222) demonstrated that a very 
active, high-affinity IL2-R in T cells might cause the functional uncoupling of the TCR 
signaling machinery through diversion of the subcellular localization of Lck to the IL2-R 
multiprotein. Consistent with this model, strong activation of Lck by the IL2-R pathway 
in iTregs may compromise the amount of Lck available in CD3/TCR complexes thereby 
altering the TCR signaling cascade. In agreement with other reports (216-218), our 
findings also suggest that Kv1.3 remains functionally linked with the pool of Lck 
susceptible to lateral mobility, providing a mechanism for redistribution of Kv1.3 in 
iTregs. Overall, our results are consistent with a model by which iTreg development 
requires a two-step process whereby cells undergo a significant round of proliferation 
followed by a rewiring of the TCR signaling inducing iTreg development.  Interestingly, 
differentiation into iTregs occurs preferentially in cells that undergo strong proliferative 
expansion, which involves continuous TCR-mediated regulation of Kv1.3 function along 
with strong activation of the AKT pathway. During transition to the differentiation stage 
and subsequent acquisition of the suppressor phenotype, the formation of new protein 
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complexes occurs concurrently with the remodeling of functional signaling paths that 
eventually dissociate AKT and Kv1.3 activities from the TCR network. We provide 
evidence for uncoupling of early TCR signaling elements, in addition to other potential 
mechanisms (173), through the competitive cross-talk between TCR and IL2-R pathways 
in cells with high IL2-dependent activity. These findings support a dynamic model by 
which the redistribution of common, key signaling components (Lck-Kv1.3) may 
represent a rapid and efficient mechanism of adapting the cell signaling machinery to a 
new functional context. The functional switch from antigen-dependent signaling in 
effector cells to cytokine-dependent responsiveness in iTregs is consistent with the 
physiological prevalence of the suppressor activity of iTregs upon antigen clearance 
(148).  
We also identified in this chapter that despite the fact that Kv1.3 relocates to the 
IL-2R, TCR induced Ca2+ flux remains intact, indicating that there is another ion channel 
compensating for its relocation. We have data to suggest a regulatory switch of K+ 
channel activity in iTregs from Kv1.3-TCR to KCa3.1-TCR. This data is of particular 
importance clinically because of an ongoing clinical trial targeting Kv1.3 activity on TEM 
cells in MS patients to inhibit the harmful effects of the effector T cells in the onset and 
progression of this disease. However, special attention should be paid to the effects of 
inhibiting Kv1.3 on iTregs, which may affect IL-2R signaling, possibly decreasing 
regulatory T cells function thus exacerbating the disease. 
Collectively, these results: (1) provide a novel mechanistic link between the 
remodeling of a signaling network and the acquisition of suppressor iTreg phenotype 
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with the selective relocation of TCR-associated proximal components; (2) support the 
importance of the finely-tuned TCR/IL2-R cross-talk in the control of T cell fate 
decisions, and (3) underscore the differential role that K+ channels may play in specific T 
cell subpopulations and/or their functional responses. 
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Chapter 5: Blockade of AKT Activity and the Association of AKT with 
SMAD3 
 
5.1 Introduction 
 One key distinguishing feature of Tregs is that the PI3K/AKT pathway 
antagonizes their development and function (145, 146). Constitutive activation of AKT 
prevents TGF-β induced FoxP3 expression in T cells (145, 146) significantly impairing 
Treg development.  Additionally, constitutive activation of AKT in nTregs leads to 
increased proliferation and concomitant abrogated suppressive capacity (147) suggesting 
that “silent” AKT is crucial for Treg development and function. Our lab has investigated 
the blockade of the AKT pathway in human iTregs and has shown that, like in mouse and 
human nTregs, the TCR-induced AKT pathway is severely inhibited (148). We further 
examined the early signaling events in the TCR signaling pathway and found a functional 
re-organization of the protein complex involved in TCR signaling in human iTregs.  
 We next investigated the functional connection between re-wiring of the TCR 
signaling pathway and the lack of AKT activation occurring in iTregs.  Ligation of the 
TCR with MHC/peptide complex results in a series of signaling cascades that activates 
PI3K, leading to the phosphorylation of PtdIns (4,5)P2 and, with lower efficiency, PtdIns 
4P, at the 3’-OH position of the inositol ring to produce PtdIns (3,4,5)P3 and PtdIns 
(3,4)P2, respectively. The production of PtdIns (3,4,5)P3 will recruit AKT to the cell 
membrane through binding by AKT’s PH domain. After translocating to the membrane, 
AKT is then phosphorylated by PDK1 and/or mTOR leading to the phosphorylation of 
both S473 and T308 activating AKT. Once activated, AKT will phosphorylate several 
114 
 
downstream targets leading to T cell activation, proliferation and differentiation. AKT 
activity is negatively regulated by several phosphatases. PTEN and SHIP1 de-
phosphorylate PtdIns (3,4,5)P3, reducing the amount of active AKT at the cell membrane. 
Additionally, PP2A and PHLPP are phosphatases that directly de-phosphorylate AKT, 
causing it to become inactivated.   
 iTreg differentiation requires blockage of the TCR AKT pathway as well as 
concurrent induction of TGF-β and IL-2 signaling pathways. TGF-β is a cytokine 
produced by lymphocytes, macrophages and dendritic cells, that affect the differentiation, 
proliferation and activation of immune cells (176, 177). Signaling through the TGF-β 
pathway will inhibit T and B cell proliferation and induce apoptosis as well as prevent 
TH1, TH2, and CTL differentiation. TGF-β signaling is initiated by ligation of 
extracellular TGF-β with TGF-βRII which will, in turn, trans-activate TGF-βRI. Once 
activated TGF-βRI phosphorylates intracellular SMAD3 enabling it to change 
confirmation thereby permitting the assembly of homo- and hetero-oligomeric complexes 
with itself or SMAD4, respectively. These SMAD3 complexes express a nuclear location 
sequence facilitating their translocation into the nucleus where they regulate transcription 
through direct DNA binding. SMAD3 complex formation enables its interaction with 
additional DNA-binding cofactors in order to achieve high affinity binding to specific 
target genes (223). One such target gene in Tregs is the enhancer of FoxP3, suggesting 
that TGF-β signaling induces FoxP3 expression during Treg development (186, 187).  
Additionally, SMAD3 associates with a FoxP3 promoter where it forms part of a 
complex that induces FoxP3 expression (224).  Intriguingly, it has been reported that 
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induction of FoxP3 enhancer activity by SMAD3 is required for iTreg development 
providing further support for this interaction (175).   
In this chapter, we set out to identify the distal TCR signaling events that govern 
AKT blockage in iTregs. We report a differential regulation of kinases to phosphatase 
ratio in iTregs compared to conventional T cells. Moreover, we report a new, non-
enzymatic function for AKT in iTregs and its cross-talk with the TGF-β pathway. These 
data have led to a better understanding of how iTregs develop and also revealed a novel 
target for potential modulation of iTreg differentiation.  
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5.2 Results 
5.2.1 Blockage of AKT activity in iTregs 
We found that protein expression of AKT was significantly higher in iTregs when 
compared to naïve and effector T cells by Western blot and flow cytometry (Figure 5.1A-
C) without a concomitant increase in AKT gene expression (Figure 5.1D), implying that 
AKT expression is regulated post-transcriptionally. Unlike in naïve and memory T cells, 
AKT phosphorylation at S473 in iTregs does not increase due to CD3 crosslinking 
(Figure 5.2A, B), therefore human iTregs also have a blockage of TCR induced AKT 
activation. P-AKT T308 levels followed the same pattern of phosphorylation as P-AKT 
S473 (Figure 5.2C). To examine whether the lack of AKT activation was due to a loss of 
the cells’ general ability to phosphorylate AKT or if it was due to a TCR-specific 
anomaly, iTregs were activated with pervanadate, a phosphatase inhibitor that leads to 
non-specific phosphorylation.  Pervanadate treatment resulted in an increase in P-AKT 
S473 levels in iTregs (Figure 5.2A, B) indicative of a TCR-specific AKT activity 
blockage. Previously we have shown that stimulation of TCR activates the ERK pathway 
in iTregs (Figure 4.1B), suggesting this blockage is not due to a complete loss of TCR 
signaling but is AKT specific (148). These results indicate a TCR-induced blockage of 
AKT activity in human iTregs and suggest that increased AKT protein expression is due 
to enhanced stability of AKT (225) resulting in subsequent AKT accumulation in the 
cytosol of Tregs.    
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Protein kinase AKT expression in iTregs 
(A) Purified human T cells were obtained and cultured for 5-6 days in iTreg polarizing 
conditions.  Lysates from 3 x 105 sorted CD25-, CD25low or iTreg cells were analyzed by 
Western blot to examine protein expression patterns. GAPDH was used as a loading 
control. (B) Total protein expression was analyzed using flow cytometry for AKT in 
various T cell subsets.  (C) Quantification of AKT MFI from human donors using flow 
cytometry. (D) Regulation of gene expression. GAPDH (housekeeping gene) and FoxP3 
(positive control) were assessed as controls. Data are representative of 3 independent 
donors.  
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: TCR-induced blockage of AKT activity in iTregs 
(A) Cultured human T cells were rested on ice for 5-6 hours and then stimulated with 
CD3 or pervanadate for 3 minutes. Flow cytometry was performed to detect phospho-
AKT S473, CD25, CD45RA, FoxP3 and CTLA4. (B) Quantification of data in A was 
analyzed using the CD3 activation index of P-AKT S473 in T cells measured by flow 
cytometry. The P-AKT S473 index was determined by taking the percentage of MFI of 
P-AKT S473 upon CD3 activation and dividing it by MFI P-AKT S473 following 
pervanadate treatment (representing the max potential of P-AKT S473). Data were 
analyzed for statistical significant using repeated measures ANOVA with a Student 
Newman-Keuls multiple comparisons post-hoc analysis. This data is representative of 5 
independent human donors. (C) The P-AKT T308 index was determined by taking the 
percentage of MFI of P-AKT T308 upon CD3 activation and dividing it by MFI P-AKT 
T308 following pervanadate treatment (representing the max potential of P-AKT T308). 
Data were analyzed for significance using repeated measures ANOVA with a Student 
Newman-Keuls multiple comparison post-hoc analysis. ***p<0.001. **p<0.01. *p<0.05. 
These data are representative of 4 independent human donors.    
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5.2.2 Blockage of AKT activity in iTregs is not due to an inability to translocate AKT to 
the membrane 
AKT activation requires its translocation to the membrane followed by sequential 
phosphorylation of AKT at S473 and T308 (74, 77, 78). Examination of AKT 
localization within T cells activated through crosslinking with anti-CD3 (Figure 5.3A) 
revealed areas of AKT-CD3 co-localization which were considered to be membrane 
bound AKT. Quantification of bound-AKT to total AKT was reported as a percentage of 
AKT recruited to the membrane (Figure 5.3B). Upon CD3 stimulation, significantly 
higher increase in AKT translocation to the membrane was observed in iTregs as 
compared to conventional T cells (Figure 5.3B).  However conventional T cells did 
exhibit a higher percentage of AKT bound to the membrane in rested cells which is most 
likely due to strong PHA induced activation in the first culture (Figure 5.3B).  The cell 
membrane contains micro domains of specialized lipid composition known as lipid rafts 
that allow localized signaling events to occur within discrete regions of the cell 
membrane.  Lipid rafts function by compartmentalizing cellular processes, by serving as 
organizing centers for the assembly of signaling molecules, and by influencing membrane 
fluidity and protein trafficking (226, 227). To explore the membrane localization of AKT, 
we analyzed the composition of lipid rafts in iTregs compared to conventional T cells 
(Figure 5.4). We found substantially more AKT localization in lipid rafts in iTregs 
compared to conventional T cells (Figure 5.4), suggesting that AKT is translocating to 
areas of the membrane involved in active signaling. Additionally, Galectin-3 (Gal3), 
which is known to inhibit the formation of large lipid macro domains from smaller micro 
domains and is thought to limit TCR clustering necessary for TCR-mediated signal 
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initiation (228), is present at high levels in the lipid rafts of iTregs but was virtually 
undetectable in the membranes of conventional T cells. These results suggest that the 
localization of Gal3 to lipid rafts in iTregs could represent a component of the cellular 
mechanism of AKT blockage. Fyn and VCP were used as positive controls for the 
separation of lipid raft verses soluble fractions (Figure 5.4). Together these findings 
indicate that the blockage of AKT activity in iTregs is not because of its inability to 
translocate to the cell membrane and imply that the defective AKT signaling could be 
due, at least in part, to the inability to form functional protein complexes downstream of 
the TCR critically important for T cell activation.   
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Figure 5.3 
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Figure 5.3:  AKT is recruited to the membrane after TCR stimulation 
(A) Conventional CD4+ T cells cultured with PHA and CD4+ T cells in iTreg 
optimization polarizing conditions (anti-CD3, IL-2, TGF-β) were obtained and rested for 
7 hours on ice. Once rested, the cells were stimulated with (CD3) or without (Mock) CD3 
antibody for 3 minutes. The cells were then treated with antibody against total AKT 
protein (green) and treated with DAPI stain for nucleus (blue). Deconvolution 
microscopy was performed to visualize the localization of AKT. This data is 
representative of three independent donors. (B) Quantification of AKT-CD3 
colocalization. For quantification of images, the colocalization highlighter plugin from 
ImageJ was used to determine the colocalization of AKT-CD3 in 100 cells for each 
population. AKT-CD3 colocalization was considered to be membrane bound AKT. 
Membrane-bound AKT was expressed as a percentage of total AKT from each cell. Data 
were analyzed for significance using repeated measures ANOVA followed by a Student 
Newman-Keuls multiple comparisons post-hoc analysis. ***p<0.001. **p<0.01. 
*p<0.05. Error bars represent the SEM.  
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Figure 5.4 
 
 
 
 
 
 
 
 
Figure 5.4: Lipid Raft components in iTregs 
Purified CD4+ T cells were subjected to ultracentrifugation on a 5-80% sucrose gradient. 
Layers were analyzed by Western Blot analysis.  
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5.2.3 iTregs express different levels of phosphatase compared to conventional T cells 
 To determine whether the lipid composition on the cell membrane of iTregs was 
affecting AKT’s ability to translocate to the membrane, we assessed the expression of 
PtdIns phosphatases that are responsible for de-phosphorylating PtdIns (3,4,5)P3 into an 
inositol derivative with lower affinity for AKT. PTEN de-phosphorylates the 3’-OH 
position of PtdIns (3,4,5)P3 generating PtdIns (4,5)P2 (81). iTregs express significantly 
higher levels of PTEN than memory or naïve T cells from the same culture (Figure 5.5).  
Overexpression of PTEN also correlated with an increase of P-PTEN in iTregs (Figure 
5.5B, D), which could confer an increase in protein stability (229, 230). Additionally, we 
did not find any significant differences in the gene expression of PTEN between any T 
cell types (Figure 5.5A). The ratio of P-PTEN/PTEN was calculated by quantifying the 
mean fluorescence intensity (MFI) of P-PTEN and PTEN respectively using flow 
cytometry (Figure 5.5E). iTregs have a significantly higher P-PTEN/PTEN ratio than 
naïve cells, implying that the differences in PTEN expression are due to an increase of 
PTEN stability. These results suggest that the overexpression of PTEN may be a key 
event in signaling leading to the blockage of AKT and subsequent development of iTregs.  
To investigate if PTEN activity is needed in the development of iTregs, we took 
advantage of the PTEN inhibitor VO-OHpic. VO-OHpic efficiency was validated in 
conventional T cells with mock, CD3 or CD3/CD28 crosslinking. Upon inhibition of 
PTEN in unstimulated or anti-CD3 conventional T cells there was no substantial 
difference in P-AKT S473 or P-Src levels compared to no inhibitor with CD3 activation 
alone. However, upon CD28 co-stimulation in the presence of PTEN inhibitor, increased 
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P-AKT S473 and P-Src were observed (Figure 5.6 A, B). These data suggest PTEN 
involvement in CD3/CD28 TCR signaling rather than in CD3 stimulation alone. The 
addition of the PTEN inhibitor to iTreg polarizing culture at various time points and 
concentrations did not affect the development of human iTregs (Figure 5.7), indicating 
that, although PTEN is overexpressed in iTregs, it does not appear to be a crucial 
signaling molecule involved in CD3 induced iTreg development.  
We also examined the expression of SHIP1, the phosphatase that de-
phosphorylates the 5’OH position of PtdIns (3,4,5)P3, generating PtdIns (3,4)P2 (83). 
SHIP1 gene expression was increased in iTregs (Figure5.8A), however SHIP1 protein 
expression in iTregs was not increased compared to other T cell populations (Figure 5.8B 
and C). These results suggest that SHIP1 is not involved in the TCR blockage of AKT 
activity seen in iTregs.  
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Figure 5.5 
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Figure 5.5: PTEN is overexpressed in iTregs 
(A) High levels of PTEN and mTOR gene expression in iTregs compared to other T cell 
populations were visualized using micro-array data. GAPDH (housekeeping gene) and 
FoxP3 (positive control) were assessed as controls. (B) Purified iTregs selectively 
express high levels of PTEN protein. Lysates from 3 x 105 sorted naïve, memory, effector 
or iTreg cells were analyzed by Western blot to detect the pattern of select protein 
expression. (C) Protein band densities were quantified by densitometry using Western 
blots shown in B. Ratios of total PTEN or phosphorylated PTEN:GAPDH are shown. 
Data were analyzed for significance using a repeated measures ANOVA followed by a 
Student Newman-Keuls multiple comparisons post-hoc analysis. Data are representative 
of 3-5 independent donors. (D) PTEN and Phospho-PTEN expression was assessed by 
flow cytometry in naïve, memory, and iTreg subsets. Quantification of PTEN and P-
PTEN mean fluorescence intensity (MFI) from human donors.  Data were analyzed for 
significance using a repeated measures ANOVA followed by a Student Newman-Keuls 
multiple comparisons post-hoc analysis. Data are representative of 4 independent donors. 
(E) Quantification of P-PTEN to PTEN ratio obtained from the MFI. Data were analyzed 
for significance using a repeated measures ANOVA followed by a Student Newman-
Keuls multiple comparisons post-hoc analysis. ***p<0.001. **p<0.01. *p<0.05.  
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Figure 5.6 
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Figure 5.6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Inhibiting PTEN in iTregs increases TCR activation only with 
CD3/CD28 stimulation 
(A) Purified human CD4+ T cells were cultured in PHA. After 5-6 days in culture, the 
cells were washed, rested on ice for 5-6 hours and then subsequently treated with either 1 
μM VO-OHpic (PTEN inhibitor) or 1 nM okadiac acid (PP2A inhibitor) for 30 minutes at 
37oC in the presence of 5% CO2. The cells were then mock-activated, CD3 activated or 
CD3/CD28 activated for 3 minutes. Lysates from 3 x 105 cells were analyzed by Western 
blot to detect the pattern of select protein expression. Data are representative of 3 
independent donors. (B) Protein band densities were quantified by densitometry from 
Western blots in A. The ratio of phosphorylated protein to total protein was normalized to 
that of mock-treated, no inhibitor cells and depicted as mock-treated (empty bars), CD3 
crosslinked (black bars) cells or CD3/CD28 crosslinked (grey bars).  
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Figure 5.7 
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Figure 5.7: Inhibiting PTEN does not affect iTreg development 
(A) Purified human CD4+ T cells were cultured in the presence of 500 nM PTEN 
inhibitor (VO-OHpic) for 6 days with inhibitor added at the indicated days. Shown is the 
percentage of cells that developed into iTregs (CD25Hi, CD45RA-, FoxP3Hi, CTLA4+ and 
CD127-). (B) Purified human CD4+ T cells were cultured in the presence of varying 
concentrations of PTEN inhibitor VO-OHpic. Inhibitor was added at the indicated 
concentration on day 0 and left in culture for 6 days. The percentage of cells that 
developed into iTregs were quantified as in A.  
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Figure 5.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: No difference in SHIP1expression in iTregs 
(A) Regulation of gene expression. High levels of SHIP1 gene expression in iTregs 
compared to other T cell populations can be visualized. GAPDH (housekeeping gene) 
was assessed as control. (B) Lysates from 3 x 105 sorted naïve, memory, effector or iTreg 
cells were analyzed by Western blot to detect the pattern of selected protein expression.  
Protein band densities were quantified by densitometry and normalized to naïve. (C) 
Protein band densities were quantified by densitometry using Western blots in B. Ratio of 
total SHIP1:GAPDH are shown. Data are representative of 3 independent donors.  
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5.2.4 Kinase activity difference in iTreg TCR signaling  
AKT is phosphorylated by mTOR at S473 and PDK1 at T308 (74, 77, 78). We 
found a trend of increased mTOR protein expression in iTregs compared to naive and 
memory cells, however it was not significant across all human donors (Figure 5.9A, B, 
C). mTOR gene expression also remained at the same level in all T cell types (Figure 
5.5A). mTOR protein complex formation is required for mTOR activity and two different 
mTOR complexes can be formed: mTOR complex 1 (mTORC1) or mTOR complex 2 
(mTORC2). mTORC2 is involved in phosphorylating AKT at S473, whereas mTORC1 is 
directly phosphorylated by AKT and is part of a negative feedback loop that inactivates 
the AKT pathway upstream of AKT. The activity of the mTOR complexes is linked to 
the phosphorylation of mTOR at the auto-phosphorylation residue S2481 (231, 232).  We 
utilized P-mTOR S2481 levels as a measure of intrinsic mTOR activity in iTregs and 
identified significantly decreased levels of P-mTOR S2481 upon CD3 stimulation in 
iTregs compared to mock stimulation, while there was no change in P-mTOR S2481 
levels detected in naïve and memory cells (Figure 5.9D, E). These results suggested that 
upon TCR stimulation, a phosphatase decreases mTOR’s activity.  Indeed, pervanadate 
treatment inhibited the decrease in P-mTOR S2481 levels, implying that this difference 
was caused by mTOR de-phosphorylation by an unknown phosphatase following TCR 
stimulation (Figure 5.9D). Quantification of TCR-induced P-mTOR S2481 MFI over 
pervandate-treated P-mTOR S2481 MFI is shown in Figure 5.9E. A significant decrease 
in P-mTOR S2481 was detected in iTregs compared to naïve and memory T cells. To 
ensure that this effect was specific to the enzymatically active residue and not simply a 
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general decrease in the phosphorylation of mTOR in iTregs, we examined the levels of 
mTOR phosphorylation by determining the extent of P-mTOR S2448. There was no 
significant difference in the P-mTOR S2448 upon TCR stimulation (Figure 5.9F) 
indicating that the differences we see in P-mTOR S2481 could be specific to that residue 
which conveys mTOR activity.  
Others have reported that the phosphatase PP2A could regulate mTOR activity 
(233, 234). We decided to determine if PP2A is responsible for mTOR inactivation in 
response to TCR stimulation in iTregs. To do this, we cultured CD4+ T cells in iTreg 
polarizing media, rested them for 5-6 hours on ice and then activated them by CD3 
crosslinking in the presence or absence of a PP2A inhibitor (okadiac acid). To test the 
efficacy of okadaic acid, we activated conventional cells in the presence of PP2A 
inhibitor and found that the levels of P-mTOR S2481 decreased, suggesting that the 
inhibitor is having an effect on mTOR activity (Figure 5.6). We found that the levels of 
P-mTOR S2481 did not increase in response to CD3 activation but rather decreased 
slightly while PP2A was inhibited, suggesting that PP2A is not the phosphatase 
regulating mTOR in iTregs (Figure 5. 10A). Additionally, we added the PP2A inhibitor 
to our cell culture system to see if inhibiting PP2A affected the development of iTregs. 
We found that there is no difference in the ability to generate iTregs if PP2A is inhibited 
(Figure 5.10B), indicating that PP2A is not involved in iTreg development.  
Although we found that mTOR was less active (phosphorylated) in response to 
iTreg TCR engagement we also wanted to evaluate the contribution of additional kinases 
to the AKT activation blockade. PI3K is the kinase that phosphorylates PtdIns (4,5)P2 
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and, with lower efficiency, PtdIns 4P,  at the 3’-OH position of the inositol ring to 
produce PtdIns (3,4,5)P3 and PtdIns (3,4)P2, respectively thus leading to translocation of 
AKT to the membrane. PI3K is composed of a regulatory subunit and a catalytic subunit. 
The regulatory subunit of PI3K can be composed of p85α, p85β or p55γ and will provide 
the PI3K with its specificity for its substrate. The catalytic subunit of PI3K can be 
composed of p110α, p110β or p110δ. We found that in iTregs, the levels of protein and 
gene expression of the regulatory subunit most often found in PI3K, p85α, were the same 
compared to other T cell populations (Figure 5.11A, B). Interestingly, while naïve and 
memory T cells do not express detectable levels of p55γ, iTregs express detectable, 
significantly higher gene and protein levels (Figure 5.11A, B). Moreover we found that 
the levels of p110β were the same in all T cell populations examined (Figure 5.11C). 
These results suggest that PI3K may target alternative substrates in iTregs compared to 
conventional T cells due to its expression of the p55γ regulatory subunit in addition to 
p85α. 
 PDK1 is one of the two kinases that phosphorylate AKT leading to its activation. 
We identified that PDK1gene expression is lower in iTregs than other T cell populations 
(Figure 5.12A). However, PDK1 protein expression was significantly higher in iTregs 
(Figure 5.12B, D). The levels of PDK1 also correlated with the increased levels of P-
PDK1 in iTregs compared to other T cell populations (Figure 5.12B, D). Quantification 
of PDK1 protein expression is shown in Figure 5.12C. Upon CD3 activation the level of 
P-PDK1 slightly decreased in all T cell populations (Figure 5.12 D, E), suggesting that 
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PDK1 activity is not augmented in iTregs compared to conventional T cells and is not 
likely a signaling molecule involved in the blockage of AKT activity.  
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Figure 5.9 
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Figure 5.9 
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Figure 5.9: mTOR is inactivated upon TCR stimulation in iTregs 
(A) Purified iTregs selectively express mTOR at levels equal to other T cell populations. 
Lysates from 3 x 105 sorted naïve, memory, effector or iTreg cells were analyzed by 
Western blot to detect the pattern of selected protein expression. Protein band densities 
were quantified by densitometry. (B) Protein band densities were quantified by 
densitometry using Western blots in A. Ratios of total mTOR:GAPDH are shown. Data 
were analyzed for significance using a repeated measures ANOVA followed by a Student 
Newman-Keuls multiple comparisons post-hoc analysis. Data are representative of 4 
independent donors. (C) mTOR Expression was assessed by flow cytometry  in naïve, 
memory, and iTreg subsets. (D) Cultured human T cells were rested on ice for 5-6 hours 
and then stimulated with CD3 or pervanadate for 3 minutes. Flow cytometry was 
performed for phospho-AKT S473, CD25, CD45RA, FoxP3 and CTLA4. (E) 
Quantification of data in D was analyzed using the CD3 activation index of P-mTOR 
S2481 in T cells measured by flow cytometry. The P-mTOR S2481 index was 
determined by taking the percentage of MFI of P-mTOR S2481 following CD3 activation 
and dividing it by MFI P-mTOR S2481 after pervanadate treatment (representing the 
maximum potential of P-mTOR S2481). Data were analyzed for significance using a 
repeated measures ANOVA followed by a Student Newman-Keuls multiple comparisons 
post-hoc analysis. **p<0.01. *p<0.05. These data are representative of 6 independent 
human donors. (F) The P-mTOR S2448 index was defined as the percentage of MFI of P-
mTOR S2448 upon CD3 activation divided by MFI P-mTOR S2448 after pervanadate 
treatment (representing the maximum potential of P-mTOR S2448). Data were analyzed 
for significance using a repeated measures ANOVA followed by a Student Newman-
Keuls multiple comparisons post-hoc analysis. This data is representative of 5 
independent human donors.  
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Figure 5.10 
 
 
 
 
 
 
 
 
Figure 5.10: PP2A is not the phosphatase regulating mTOR 
(A) Cultured human T cells were rested on ice for 5-6 hours then treated with a PP2A 
inhibitor (okadaic acid) for 30 minutes at 37oC. The cells were then stimulated with CD3 
for 3 minutes. Flow cytometry was performed for phospho-mTOR S2481, CD25, 
CD45RA, FoxP3 and CTLA4. iTregs were identified by their phenotype of high 
expression of CD25, FoxP3, CTLA4 and CD45RA negative. MFI of P-mTOR S2481 is 
shown following CD3 activation in iTregs. Inhibiting PP2A does not appear to effect the 
levels of P-mTOR S2481. Data are representative of three independent donors. Data were 
analyzed by Student’s t-test. Error bars represent SEM. Representative of 3 independent 
donors. (B) Purified human CD4+ T cells were cultured for 6 days with vehicle or the 
inhibitor of PP2A (1nM okadiac acid) added at the indicated day. After 6 days in culture, 
the cells were analyzed for the percentage of cells that developed into iTregs based on 
criteria above. Error bars represent SEM. Representative of 3 independent donors. 
Adding PP2A inhibitor to our culture system did not affect the development of iTregs.  
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Figure 5.11 
 
Figure 5.11:  iTregs express significant amount of p55γ 
(A) Regulation of gene expression. High levels of p55γ gene expression were found in 
iTregs compared to other T cell populations, however p85α remained the same 
throughout each T cell population.  GAPDH (housekeeping gene) and FoxP3 (positive 
control) were assessed as controls. (B) Purified iTregs selectively express high levels of 
p55γ protein. Lysates from 3 x 105 sorted naïve, memory, effector or iTreg cells were 
analyzed by Western blot to detect the pattern of selected protein expression. The same 
membrane was sequentially stripped and reprobed. Protein band densities were quantified 
by densitometry. (C) Purified iTregs express relatively identical levels of p110β protein 
to other T cell populations. Lysates from 3 x 105 sorted naïve, memory, effector or iTreg 
cells were analyzed by Western blot to detect the pattern of selected protein expression. 
Protein band densities were quantified by densitometry.  
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Figure 5.12 
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Figure 5.12 
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Figure 5.12 PDK1 activity is not diminished in iTregs 
(A) Regulation of gene expression. Lower levels of PDK1 gene expression were found in 
iTregs compared to other T cell populations. GAPDH (housekeeping gene) was assessed 
as control. (B) Purified iTregs selectively express higher levels of PDK1 compared to 
other T cell populations. Lysates from 3 x 105 sorted naïve, memory, effector or iTreg 
cells were analyzed by Western blot to detect the pattern of selected protein expression. 
Protein band densities were quantified by densitometry. (C) Protein band densities were 
quantified by densitometry using Western blots in B. Ratio of total PDK1 and phospho-
PDK1:GAPDH are shown. Data were analyzed for significance using a repeated 
measures ANOVA followed by a Student Newman-Keuls multiple comparisons post-hoc 
analysis. N=3-5 independent donors. (D) PDK1 and P-PDK1 levels were assessed by 
flow cytometry  in naïve, memory, and iTreg subsets. (E) Cultured human T cells were 
rested on ice for 5-6 hours then stimulated with CD3 or pervanadate for 3 minutes. Flow 
cytometry was performed for phospho-PDK1, CD25, CD45RA, FoxP3 and CTLA4. (F) 
Quantification of data in E was analyzed using the CD3 activation index of P-PDK1 in T 
cells measured by flow cytometry. The P-PDK1 index was defined as the percentage of 
MFI of P-PDK1 upon CD3 activation divided by MFI P-PDK1 after pervanadate 
treatment (representing the max potential of P-PDK1). Data were analyzed for 
significance using a repeated measures ANOVA followed by a Student Newman-Keuls 
multiple comparisons post-hoc analysis. **p<0.01. *p<0.05. These data are 
representative of 4 independent human donors 
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5.2.5 AKT associates with SMAD3 and regulates SMAD3’s transcriptional activity in 
iTregs 
The accumulation of significant levels of inactive AKT suggests a possible 
physiologic role for its inactive form. There is evidence to suggest that, in some cell 
types, AKT binds to the transcription factor SMAD3 (235-237). This was particularly 
intriguing to us because TGF-β signaling, which activates SMAD3, is required during 
iTreg development (182). Upon phosphorylation, SMAD3 becomes activated and 
translocates into the nucleus where it regulates transcription, typically upregulating pro-
apoptotic factors. However, SMAD3 upregulates the expression of FoxP3 in iTregs, 
implying that SMAD3 activity is critical during iTreg differentiation (187, 238). iTregs 
express significantly more SMAD3 protein than other T cell populations, which 
coincided with an increase in the P-SMAD3 levels (Figure 5.13A, B), indicating a 
robustly activated TGF-β signaling pathway in iTregs. These data provide a possible 
mechanism for upregulated FoxP3 expression by SMAD3 during iTreg development 
(187, 238). To determine if AKT-SMAD3 association occurs in human iTregs, we 
immunoprecipitated AKT and then probed for SMAD3. We observed more AKT and 
SMAD3 association in iTregs than in conventional T cells (Figure 5.14A). Confirmation 
of this relationship was obtained by reversing the immunoprecipation (Figure 5.14B). We 
have determined that AKT localizes to the membrane and have demonstrated a unique 
interaction between AKT and SMAD3. Given that SMAD3 must be activated at the 
membrane and translocate to the nucleus to regulate transcription, we next sought to 
investigate the location of AKT-SMAD3 interaction.  iTregs and conventional T cells 
were stained with AKT and SMAD3 antibodies in order to examine their intracellular 
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location via confocal microscopy.  AKT and SMAD3 appeared to colocalize in the 
cytoplasm of iTregs (Figure 5.15), suggesting that AKT-SMAD3 association could be 
negatively regulating SMAD3 transcriptional activity by inhibiting its translocation into 
the nucleus.  Conventional T cells and iTregs were transfected with a SMAD3 reporter 
plasmid (pGL3 Basic CAGA12 Luc) (192) containing a series of CAGA repeats linked to 
a luciferase reporter which allowed indirect measurement of SMAD3 activity through 
luminescence (Figure 5.16A). We found that conventional T cells had significantly 
higher SMAD3 activity compared to iTregs (Figure 5.16B), indicating that AKT-SMAD3 
association regulates SMAD3 transcriptional activity. These results illustrate a new, non-
enzymatic function of AKT in iTregs by way of an AKT-SMAD3 interaction that inhibits 
SMAD3 activity, and has revised our view of the signaling events occurring in iTreg 
development. We hypothesize that iTreg development involves a two-step process 
(Figure 5.17), in which T cells first undergo a significant round of proliferation that 
requires high levels of AKT activity and rapid AKT turnover with concomitant FoxP3 
induction by SMAD3 (Figure 5.17). Once divided, the cells then undergo rewiring of 
their signaling network which leads to differentiation of the T cells into iTregs.  
Subsequent blockage of AKT activity results in AKT accumulation in the cytoplasm 
which negatively regulates SMAD3 activity by preventing SMAD3 translocation into the 
nucleus via its physical association with AKT.  
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Figure 5.13 
 
Figure 5.13: iTregs express high levels of SMAD3 
(A) Total protein expression was analyzed using flow cytometry for SMAD3 in various T 
cell subsets. Quantification of SMAD3 MFI from 4 independent human donors. (B)  
Phospho-SMAD3 expression was assessed by flow cytometry in naïve, memory, and 
iTreg subsets. Quantification of P-SMAD3 MFI from 4 independent human donors. Data 
were analyzed for significance using a repeated measures ANOVA followed by a Student 
Newman-Keuls multiple comparisons post-hoc analysis. *p<0.05. 
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Figure 5.14 
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Figure 5.14: SMAD3 associates with AKT in iTregs 
(A) iTregs which were induced in optimization iTreg polarizing media and conventional 
T cells were immunopreciptated with agrose beads bound to AKT antibody. The 
immunopreciptate was then run on an SDS-PAGE gel and analyzed via Western blot. 
Blots were probed for SMAD3 or AKT. The ratio of SMAD3/AKT was calculated using 
densitometry measurements of protein expression. (B) iTregs and conventional T cells 
were immunopreciptated with agrose beads bound to SMAD3 antibody. The 
immunopreciptate was then run on an SDS-PAGE gel and analyzed via Western blot. 
Blots were then probed for AKT or SMAD3. The ratio of SMAD3/AKT Bound was 
calculated using densitometry measurements of protein expression.  
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Figure 5.15 
 
Figure 5.15: SMAD3-AKT association occurs in the cytoplasm of iTregs 
Confocal microscopy was performed on sorted naïve, memory, effector and iTregs. Cells 
were stained for total AKT (green) and SMAD3 (red) protein, plus DAPI (blue). 
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Figure 5.16 
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Figure 5.16: SMAD3 transcriptional activity 
(A) Investigation of SMAD3 transcriptional activity was performed using the pGL3 
Basic MLP (CAGA)12 Luciferase plasmid, which contains a SMAD3 CAGA box 
repeated 12 times linked to a luciferase reporter. SMAD3’s transcriptional activity 
induces luciferase production in the cells. (B) PHA-stimulated (effector cells) and iTreg 
cells which were cultured in our optimization iTreg polarizing media were transfected 
with a pGL3 Basic MLP (CAGA)12 Luciferase plasmid (SMAD3 Activity Reporter) and 
pGLRP (Transfection control) at day 5, lysed and analyzed for Luciferase and Renilla 
levels. Relative Luciferase units are luciferase/renilla. Two tailed paired student’s t test 
was performed * p<0.05. 
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Figure 5.17 
 
 
Figure 5.17: Model of iTreg development 
iTreg development may consist of two main steps. CD4+ T cells first undergo a 
significant round of proliferation in culture, during which AKT is highly active and there 
is a rapid AKT protein turnover in the cells. At this early stage, SMAD3 signaling 
induces FoxP3 induction in the T cells. Once divided, the cells then undergo a rewiring of 
signaling networks which leads to differentiation of the T cells into iTregs. There is a 
blockage of AKT activity in iTregs due to these changes in signaling leading to an 
accumulation of AKT protein in the cytoplasm of the cells. AKT-SMAD3 then associate 
with each other in the cytoplasm of the cells, thereby regulating SMAD3’s transcriptional 
activity.  
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5.3 Summary 
 We have demonstrated a blockage of the TCR-dependent AKT activation in 
human iTregs also present in other regulatory T cell subsets that could be critical for 
regulatory T cell development and function. Moreover, we have shown that this blockage 
of AKT activity is not due to a general failure of AKT activation, but appears to be TCR 
specific. AKT accumulates in iTregs most likely due to its inability to become activated 
and subsequently degraded. We set out to determine the cause of AKT activity blockage 
in iTregs. We found that AKT was recruited to the membrane upon TCR stimulation and 
localizes to lipids rafts. iTregs have a different protein composition in lipid rafts 
compared to conventional T cells suggesting that the defective AKT signaling could be 
due, at least in part, to the inability to form functional protein complexes. In addition to 
intracellular localization, several kinases and phosphatases are crucial to the activation 
and inactivation of AKT in the TCR signaling network. iTregs exhibit an overexpression 
of the phosphatase PTEN compared to conventional T cells, however inhibition of PTEN 
resulted in no effect on the differentiation of iTregs. Our data suggest that PTEN is 
involved in TCR signaling when CD3 and CD28 are stimulated, but not when CD3 is 
stimulated alone.  Although the overexpression of PTEN could be critical for inhibiting 
TCR AKT activity following CD3-CD28 costimulation, we do not use CD28 for 
development of human iTregs. Thus, inhibiting PTEN has no effect on the ability to 
generate iTregs in our culture system. Additionally, we found that there is no difference 
in the expression of SHIP1 in iTregs compared to conventional T cells, precluding the 
role of SHIP1 in differential iTreg AKT pathway signaling.  
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Having found no evidence to support the involvement of differential intracellular 
AKT localization, PTEN, or SHIP1 in the inactivation of AKT in iTregs, our attention 
then turned to the kinases that activate AKT. As mTOR is known to induce AKT 
activation through phosphorylation, our observation of decreased mTOR activity upon 
TCR stimulation in iTregs suggests that this could be a key step in the blockage of AKT 
activity. Treatment with a phosphatase inhibitor (pervanadate) blocked the TCR induced 
inhibition of mTOR activity, suggesting mTOR is inactivated by a phosphatase. PP2A 
has been implicated as the phosphatase regulating mTOR’s activity by others (233, 234), 
however pharmacologic inhibition of PP2A did not increase TCR induced mTOR activity 
in our hands. Which phosphatase regulates mTOR activity in iTregs remains unclear. 
Additionally, PDK1 and P-PDK1 levels were increased in iTregs, suggesting that AKT 
blockage does not result from decreased PDK1 activity. Lastly, we found that PI3K 
subunits in iTregs are differentially expressed. Human iTregs exhibit significantly more 
of the regulatory subunit p55γ than conventional T cells, indicating that PI3K may have 
different as yet unidentified substrates in iTregs, thus making it an attractive target for 
further study. These results suggest that the TCR-induced blockage of AKT activity is not 
necessarily caused by one signaling molecule, but is the result of a combination of 
differential regulatory events in the TCR pathway leading to blockage of AKT. 
 Having identified several key signaling changes that could lead to TCR-induced 
AKT inhibition, we next wanted to investigate the role of AKT itself in iTregs. We 
demonstrated that AKT accumulates in iTregs which leads to AKT-SMAD3 association. 
AKT-SMAD3 association occurs in the cytoplasm, indicating it is regulating SMAD3’s 
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transcriptional activity. SMAD3 activity was significantly lower in iTregs despite the 
overexpression of SMAD3 protein and higher P-SMAD3 levels. Though we did not 
examine TGF-β induced SMAD3 independent signaling, its role in iTreg development 
cannot be discounted by our studies and further investigation of SMAD3 independent 
signaling is warranted. We hypothesize that the AKT-SMAD3 association is a critical 
late step in iTreg development, due to the fact that SMAD3 signaling is required during 
the early iTreg development to induce FoxP3 expression, yet overactivation initiates 
apoptosis. These studies demonstrate the attractiveness of the AKT-SMAD3 association 
as a potential target for modulating iTreg development in the treatment of disease.   
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Chapter 6: Discussion 
 
6.1 Overcoming the deficiency in generating and studying iTregs 
 The critical importance of Tregs in the human immune system is made evident by 
the numerous diseases associated with their dysregulation (17). iTregs comprise the 
majority of the circulating peripheral Tregs in the human body (25). It has been shown 
that transfer of Tregs into mice is beneficial in murine models of autoimmune diseases 
and/or chronic inflammatory diseases like colitis (194), type I diabetes (42), RA and graft 
versus host disease (195). However, current limitations, such as inadequate number, the 
fidelity of Treg homing specificity, and insufficient purity and stability, must be 
overcome before the manipulation of Tregs can serve a useful therapeutic role.  Prior to 
the work outlined in this dissertation, we were unaware of any cell culture systems 
available that could generate large amounts of human iTregs ex vivo. Therefore, our lab 
has established an innovative ex vivo cell culture system that mimics in vivo iTreg 
development (188).  This system allows for the discrimination and comparison of naïve, 
memory and iTreg T cell populations simultaneously within a single donor over the 
course of six days in culture.  Cells that differentiate into iTregs arise from a highly 
proliferative population of T cells that start to mature around day three in culture and then 
progressively increase in quantity and expression of iTreg-specific cell markers over the 
next several days until 20-35% of cells have differentiated into iTregs. Optimization of 
iTreg development results in differentiation of approximately 80% of the cells into 
iTregs.  Human iTregs exhibit high levels of FoxP3, CTLA4, GITR and are CD127 
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negative. Comprehensive examination of human iTreg phenotype revealed expression of 
CD86, a marker usually expressed by APCs, and not expressed on other T cell subsets, 
may facilitate an iTreg’s interaction with other T cells.  Additionally, our finding that 
CCR2 and CCR1 are present on human iTregs suggests they can traffic to sites of 
inflammatory chemokine production. iTregs also exhibit high levels of CD58, which 
when bound to its ligand CD2 optimizes immune recognition and T cell expansion (202).  
CD58/CD2 ligation strengthens the interaction between a Treg cell and a target 
conventional T cell (203), which may be critical for efficient suppression. CD30, a 
marker of activated T cells, was displayed on iTregs as well, and has been proposed to be 
involved in the regulatory function of Tregs in vivo (205).  Human iTregs have reduced 
levels of CD31 normally expressed on naïve cells implying they may undergo a change in 
the pattern of migration in vivo. CD31 is a major constituent of the endothelial cell 
intracellular junction.  The expression of CD31 on the cell surface of T cells has been 
shown to modulate their transmigration across endothelial cell barriers (239-241). These 
results suggest that human iTregs may possibly be trafficking to different areas in vivo 
compared to naïve T cells likely by exploiting a mechanism other than CD31. Lastly, 
human iTregs have a higher expression of Galectin 3 compared to effector T cells (Fig. 
5.4).  Galectin 3 is known to prevent small microclusters on the membrane to form active 
macrocomplex (228). Therefore, iTregs may have an inability to form large 
marcocomplexes necessary for optimal TCR-mediated signal initiation upon TCR 
stimulation. The expression pattern of these phenotypic markers is consistent with Tregs. 
In the presence of iTregs, effector T cell proliferation dramatically decreased confirming 
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the suppressor ability of the iTregs generated by our culture system. In addition, our data 
suggest that iTreg suppression appears to be mediated through both cell-to-cell contact 
and secretion of soluble factors, such as IL-10. 
 Together, these data create a working model of iTreg development.  We 
hypothesize that iTregs develop from CD4+ T cells via a two-step process.  First, CD4+ T 
cells must undergo a substantial round of proliferation, followed by the rewiring of their 
TCR signaling network which subsequently induces transformation of CD4+ T cells into 
iTregs.   
6.2 TCR proximal signaling events involved in iTreg development 
 A better understanding of the basic biology of iTregs is the first step in their 
development as a therapeutic treatment.  One of the earliest known events in iTreg 
signaling is the failure to activate the PI3K/AKT pathway (145).  Constitutive activation 
of AKT inhibits the differentiation of T cells into iTregs through the blockage of FoxP3 
induction and, additionally, leads to the loss of suppressor function in nTregs (146, 147).  
These results support the need for AKT that is “silent” in order to sustain Treg 
development and function. However, the specific mechanism by which AKT activation is 
blocked remains unknown. 
We examined the events upstream and downstream of AKT following TCR 
stimulation to elucidate the events surrounding blockage of AKT. We demonstrated 
partial activation of the TCR signaling pathway in iTregs compared to conventional T 
cells and the failure of AKT to become activated upon TCR induction in iTregs. In 
contrast, upon crosslinking with anti-CD3, ERK activation is highly effective in iTregs, 
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suggesting that the blockage of AKT activity and the selective activation of TCR are not 
secondary to a general failure of TCR signaling; rather, these are events specific to the 
AKT pathway. 
iTregs also exhibited high levels of active Lck at rest that did not increase upon 
TCR ligation, independent of total Lck protein or gene expression.  These data indicate 
that Lck may be activated by an alternative signaling pathway in iTregs.  iTregs exhibit 
high expression of CD25, the IL-2Rα subunit which is expressed on activated and 
regulatory T cells, which generates a high affinity IL-2R complex.  We observed the 
association of Lck with the highly active IL-2R upon IL-2 treatment in iTregs.  Lck is a 
key proximal molecule in TCR signaling that initiates the downstream events that could 
direct AKT inactivation in iTregs.  The first demonstration of the uncoupling of Lck from 
the TCR involved its relocation from TCRβ to CD3 ε-chain to regulate calcium flux in 
thymocytes and lymph node T cells, and was later found to relocate to CD45, CD4 and 
CD8 in mature primary T cells (242-245).  The displacement of Lck to the high affinity 
IL-2R has also been demonstrated in a mouse CD4+ T cell clone where Lck functionally 
uncouples from the TCR signaling machinery through diversion of the subcellular 
localization of Lck to the IL-2R multiprotein (222).  This finding suggests that there is a 
pool of Lck that can localize from the TCR to the IL-2R and may provide another level of 
iTreg TCR regulation. 
Further downstream of Lck, we found only partial LAT phosphorylation in 
iTregs, which is concordant with our observation of partially decreased PLCγ 
phosphorylation, suggesting TCR-induced Ca2+ flux may also be negatively affected. 
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Kv1.3 is critical for hyperpolarizing  the plasma membrane in response to the change in 
potential following TCR-induced Ca2+ flux (161). Kv1.3 levels were the same throughout 
all T cell populations we examined, however Kv1.3 activity was very weak in iTregs 
following TCR ligation, indicating a functional dissociation between TCR and Kv1.3. 
Lck has been shown to be functionally linked to the Kv1.3 channel during the formation 
of the immune synapse (216-218). Therefore, because Lck relocates to the IL-2R, Kv1.3 
could relocate with it.  Our finding that Kv1.3 is activated in response to IL-2 in iTregs 
provides evidence of a possible mechanism for the inhibition of AKT through a 
functional uncoupling of key proximal signaling molecules from the TCR and their 
relocation to the highly active IL-2R in iTregs.   
As we determined that Kv1.3 relocates to the IL-2R in iTregs, we next examined 
the integrity of Ca2+ flux in response to TCR stimulation in iTregs.  Ca2+ flux remained 
intact in iTregs, suggesting compensation for the lack of Kv1.3 activity at the TCR by 
another ion channel.  KCa3.1 was subsequently found to be overexpressed in iTregs, and 
upon its inhibition Ca2+ flux was suppressed, suggesting KCa3.1 may be responsible for 
regulating the TCR-induced Ca2+ flux in iTregs. These data implicate a regulatory switch 
of K+ channel activity in iTregs that may constitute a key contributing factor in signaling 
rewiring associated with the development of human iTregs. These novel findings indicate 
an even higher level of TCR receptor regulation in iTregs, where the movement of 
protein complexes from the TCR is critical for differentiation.  This complex 
reorganization is more than likely a key event, the understanding of which will be 
important in future iTreg signaling studies. We hypothesize that the interplay between the 
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IL-2R and the TCR may also be shared by other cytokine pathways. IL-15 is a cytokine 
that is structurally similar to IL-2 and signals through a complex composed of the IL-2Rβ 
chain and the common γc chain (246).  IL-15 is critical to providing survival signals that 
maintain memory T cells in the absence of antigen. We found that Lck associates with the 
IL-2Rβ chain in iTregs, therefore it is possible that Lck and Kv1.3 can also relocate to the 
IL-15R in memory T cells, and this relocation may be critical for maintaining survival of 
the memory T cells.  These studies shed light on the value of understanding the regulation 
of functional uncoupling of protein complexes from the TCR and the cross talk between 
cytokine pathways. 
Aside from AKT pathway inactivity, very little was known about iTreg-specific 
signaling events prior to the studies outlined in this dissertation.  We found that key 
signaling events upstream of AKT are relocated to the highly active IL-2R in iTregs and 
have provided new insight into the targeting of Kv1.3 channels for the treatment of 
autoimmune disease.  Studies are underway targeting TEM cells in MS patients through 
inhibition of the Kv1.3 channel (166).  These studies have found that inhibiting Kv1.3 
channels helps to control the pathogenicity of TEM cells, however given our findings that 
Kv1.3 is located at the IL-2R in iTregs and that it may be critical in maintaining a steady 
population of peripheral Tregs, targeting Kv1.3 could lead to the loss of iTreg function, 
thus exacerbating the disease. Special consideration should be given to the effect of 
Kv1.3 inhibition on iTreg function when modulating its function in a therapeutic setting 
in vivo.   
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Other potential applications for inhibiting Kv1.3 would be in a mixed T cell 
culture ex vivo, in which Kv1.3 inhibition may help select a pure population of iTregs 
ready for re-infusion into an autologous donor. One of the hurdles that must be overcome 
before iTregs can be used for therapeutic treatment is the ability to generate a pure 
population of iTregs.  This task is made difficult by the phenotypic similarities between 
iTregs and effector T cells, which can also be generated during ex vivo expansion. As it is 
known that Kv1.3 activation is a necessary step in effector T cell activation but is no 
longer functionally linked to the TCR in iTregs, one possible solution to this problem 
would be to inhibit Kv1.3 to preferentially or selectively prevent TCR-dependent effector 
T cell proliferation and facilitate the generation of a pure population of iTregs ex vivo. 
6.3 TCR distal signaling events involved in iTreg development   
Our investigation turned to the differential regulation of kinases and phosphatases 
that control AKT’s activity further downstream of the TCR.  AKT protein expression was 
shown to be significantly greater in iTregs compared to conventional T cells, however 
AKT transcript levels were the same compared to other T cell populations.  Additionally, 
though there were higher levels of AKT in iTregs, its activity did not increase in response 
to TCR stimulation, suggesting that AKT accumulation in iTregs is most likely because 
of decreased degradation.  We found that AKT translocates to the membrane upon TCR 
stimulation in iTregs, implying that AKT blockage occurs after its recruitment to the 
membrane. 
PTEN and SHIP1, phosphatases that regulate the level of PtdIns (3,4,5)P3 upon 
TCR induction in T cells, were evaluated in iTregs.  We uncovered no difference in the 
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expression of SHIP1 in iTregs compared to conventional T cells, suggesting that SHIP1 
may not have a role in differential AKT pathway signaling in iTregs. However, this 
should be examined in a functional assay to completely rule out this possibility. Although 
human iTregs express higher levels of PTEN compared to effector T cells, its inhibition 
did not affect the development of iTregs in our system.  Additionally, our data suggest 
that PTEN is involved in TCR signaling when CD3 and CD28 are stimulated, but not 
under CD3 stimulation alone.  Though PTEN overexpression could be critical for 
inhibiting TCR-induced AKT activity following CD3-CD28 costimulation in other 
systems or in vivo, its inhibition had no effect in our system, as we do not need CD28 for 
iTreg induction.  The discrepancy could be explained by the signaling pathways initiated 
by CD3 and CD28 crosslinking, along with the function of the cell types that need both 
signaling molecules.  Naïve T cells require TCR/CD3 stimulation along with co-
stimulation through CD28 to develop, activate and  differentiate into a conventional T 
helper cell (247).  CD28 co-stimulation induces the production of IL-2, increasing T cell 
metabolism, proliferation and differentiation through the strong activation of the AKT 
pathway (247).  Memory T cells, however, only need CD3 stimulation to become active 
and lead to AKT activation, but to a lesser extent.  In culture conditions where α-CD28 is 
not included, we believe the iTregs generated develop primarily from memory T cells, 
and that PTEN may not play a role in TCR-dependent AKT pathway regulation..  
However, when iTregs are generated from naïve cells in media containing α-CD28, a 
strong AKT activation unfavorable to iTreg development could be induced.  In this 
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instance, PTEN regulation is crucial to dampen the response inhibiting AKT activation at 
the CD28 receptor. 
Another potential regulatory role for PTEN overexpression in iTregs could be 
linked to the observation by others that PTEN inhibits IL-2R mediated expansion of 
Tregs, and that this regulation by PTEN is important for peripheral homeostasis in murine 
Tregs in vivo (174).  This is interesting to us as we have already established that other key 
proximal signaling molecules, Lck and Kv1.3, translocate to the IL-2R in human iTregs. 
Thus, the possibility exists that PTEN is also active at the IL-2R in human iTregs; 
however, further investigation is needed for confirmation of this hypothesis. 
 Activation of AKT occurs through phosphorylation by mTOR at S473 and PDK1 
at T308 (74, 77, 78).  We identified a trend of increased mTOR protein expression in 
iTregs compared to naïve and memory cells, in some, but not all human donors.  
Interestingly, upon CD3 stimulation, phospho-mTOR levels decreased in iTregs, 
suggesting that mTOR inhibition in response to TCR activation could lead to blockage of 
AKT activity.  These data fit very well with previous data using the mTOR inhibitor 
rapamycin, an immunosuppressive drug currently approved to prevent organ rejection, 
especially useful in kidney transplants.  Rapamycin enables the expansion and induction 
of murine and human Tregs (248-250) and highly increases human iTreg suppressor 
activity in both in vitro and in vivo (248).  Combined, these data highlight the necessity of 
mTOR inhibition in Tregs and suggest another phosphatase in the regulation of mTOR’s 
activity in iTregs after TCR stimulation. PP2A is a phosphatase known to regulate mTOR 
activity (233, 234). However, inhibition of PP2A activity with okadaic acid did not result 
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in increased mTOR activity in iTregs. Together, these findings identify mTOR inhibition 
as a crucial step in the differentiation of iTregs, and accentuate the need to identify the 
phosphatase responsible for its regulation.   
 AKT is also activated in response to TCR stimulation by another kinase, PDK1.  
PDK1 protein expression is increased in iTregs compared to conventional T cells, which 
correlates with an increase in its phosphorylated form.  These data suggest that PDK1 
activity does not diminish in iTregs, and is unlikely to lead to the blockage of AKT 
activity.  However, increased PDK1 protein expression could compensate for the lack of 
AKT activity in iTregs, as the downstream targets of PDK1 and AKT appear to overlap 
(251). Confirmation of this compensatory relationship will require further investigation.     
 AKT recruitment to the membrane requires phosphorylation of phosphoinositols 
by the kinase PI3K. When PI3K expression was examined in iTregs, we found 
substantially higher incorporation of the p55γ subunit responsible for recruiting PI3K to 
its targets, versus conventional T cells.  These data suggest that PI3K may have different 
downstream targets in iTregs than in conventional T cells, leading to a different signaling 
profile downstream of PI3K and subsequent rewiring of signaling pathways. It is 
important to note that we did not find a difference in the ability of PI3K to recruit AKT to 
the membrane upon TCR stimulation, indicating that PI3K still activates 
phosophoinostiols and that it produces enough PtdIns (3,4,5)P3 to recruit AKT to the 
membrane, but could also induce other signaling pathways.  A definitive role for PI3K in 
AKT recruitment to the membrane will be necessary for further understanding of this 
signaling pathway.  
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 Having identified several key signaling molecules that lead to the inactivation of 
AKT in iTregs, we next set out to examine the role of AKT itself in iTreg differentiation. 
Significantly higher AKT levels suggest a physiologic function for AKT within the cell 
during iTreg development. Others have shown that AKT associates with the transcription 
factor SMAD3 in various cell lines (235-237) and that, in some instances, the AKT-
SMAD3 association regulates AKT activity while in others, SMAD3 activity is affected 
(235-237). This was intriguing to us as TGF-β signaling, which is responsible for 
SMAD3 activation, is necessary for iTreg development.  We found significantly more 
SMAD3 and phospho-SMAD3 in iTregs compared to conventional T cells suggesting an 
abundance of both AKT and SMAD3 may be leading to their interaction in iTregs. 
Interestingly, AKT was identified to associate with SMAD3 in the cytoplasm of iTregs.  
SMAD3 activity was significantly decreased in iTregs compared to conventional T cells, 
implying that AKT-SMAD3 association prevents SMAD3 from translocating into the 
nucleus of the cell where it can regulate transcription.  To the best of our knowledge, 
these data present the first report of a non-enzymatic function for AKT in human iTregs.  
We speculate that the AKT-SMAD3 interaction provides temporal regulation critical for 
iTreg development that allows SMAD3’s induction of FoxP3 early during development, 
but later inhibits SMAD3’s activity, preventing SMAD3 induced apoptosis. Additionally, 
we suggest that the AKT-SMAD3 association is a novel target for the modulation of 
iTreg development and maintenance.  The prevention of this protein association can 
potentially promote a pro-inflammatory response, and could be useful in cancer and some 
infections which reduce immunosurveilance as part of its evasion strategy. 
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6.4 Modulation of the AKT pathway in iTreg development in the clinic: from bench 
discovery to valuable clinical tool 
 Unlike mouse work or cell culture work with human-derived cell lines that need 
to be confirmed in humans before use as a human therapeutic, our work is directly 
translatable as we are working directly with primary human T cells. We have found that 
the TCR induced AKT pathway is inactived in iTregs when compared to effector T cells 
and have elucidated the cause of this blockage. The AKT signaling pathway is integral to 
cell survival and has been closely associated with development and progression of tumors 
(252). Therefore, the AKT pathway is widely targeted in cancer therapeutics. However, 
whether or not the AKT pathway is a beneficial target in the development of iTregs 
remains to be determined. We hypothesize that targeting the AKT pathway to inhibit 
iTreg development presents a novel treatment pathway in diseases associated with over-
active Tregs.  In certain types of cancer, it is thought that Tregs are either recruited to the 
microenvironment of the tumor or are induced in the microenvironment of the tumor 
itself (253, 254) and, once there, are facilitating the tumor’s evasion of immune system 
recognition. If this concept of Treg assistance in tumor concealment is accurate, 
modulation of iTreg development and maintenance at the site of the tumor would be 
highly beneficial to cancer patients.  We hypothesize that direct modulation of iTreg 
development through targeting the AKT pathway by specifically inhibiting the 
colocalization of AKT with SMAD3 will induce apoptosis in iTregs and possibly 
alleviate the blockage of the immune system tumor recognition.   
 Targeting the AKT pathway could also be beneficial in cases where there are 
inherent defects in iTreg generation or function. Mouse models of chronic inflammatory 
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disease (i.e., IBD, asthma, type I diabetes)  have demonstrated that treatment with ex vivo 
Tregs helped ameliorate disease pathology (41). In humans, large-scale ex vivo 
generation of Tregs through inhibition of the AKT pathway followed by repatriation 
within the patient could help to ameliorate the disease.  Though we have overcome the 
deficiencies in the ability to generate a sufficient number of iTregs, there are still 
roadblocks which we must overcome to ensure the viability of a treatment like this.  It is 
essential to confirm that iTregs generated ex vivo will not revert back into an 
inflammatory phenotype, thus worsening the disease. Additionally, we have yet to 
decipher how iTregs traffic to specific tissues or organs in the body. Patients with JIA or 
MS have normal functional Tregs, however their effector T cells are resistant to Treg 
suppression (36, 44).  In this case, modulating the AKT pathway in iTregs would not 
affect patient outcome as their Tregs appear to be suppressive ex vivo. Surprisingly, 
however, it has been shown that effector T cells found in the joints of JIA patients have 
an overactive AKT pathway (44).  Therefore, targeting the AKT pathway in effector T 
cells could possibly reduce the pathologic effects of effector T cell function in JIA 
patients by decreasing the inhibition of effector T cell suppression by the Tregs in the 
microenvironment.  However, in MS patients the presence of an overactive AKT has not 
been identified as yet. Overactive AKT in MS patients would be need to verified before a 
direct hypothesis on how to treat these patients could be formulated.  Regardless of the T 
cell type responsible for pathology, we postulate that targeting the AKT pathway for the 
modulation of iTreg development is a novel target for therapeutic treatment. 
 
170 
 
6.5 Future Directions 
 We have presented evidence herein for a mechanism of the inactivation of AKT 
in iTregs in which several signaling pathways are reorganized. A relocation of K+ ion 
channels from the TCR to the IL-2R in iTregs and a regulatory switch to KCa3.1 usage 
could regulate TCR-induced Ca2+ flux in iTregs, however confirming these results 
through high-throughput patch clamp technology will be necessary to definitively 
establish KCa3.1’s role.  It will be important to understand the functional role of Kv1.3 at 
the IL-2R and whether or not it is fundamental to the maintenance and function of Tregs.  
If Kv1.3 activation is indeed critical for iTreg function, special consideration of its role in 
iTreg function should be taken into account when using Kv1.3 inhibitors to treat 
autoimmune disease. 
 Additionally, we have shown increased expression of the PI3K subunit p55γ in 
iTregs compared to conventional T cells.  We hypothesize that p55γ is critical for iTreg 
development.   PI3K is a critical player in the TCR pathway that will generate PtdIns 
(3,4,5)P3 subsequently leading to activation of second messengers like IP3 and AKT.  In 
iTregs there is a significantly higher level of expression of p55γ versus naïve cells 
suggesting that this key signaling molecule may have different downstream targets in 
iTregs versus conventional T cells which utilizes p85α leading to a differential signaling 
pattern. A stable knockdown of p55γ in human CD4+ T cells would allow us to determine 
if p55γ is necessary for iTreg development.  After demonstrating the need for p55γ, 
elucidating the targets of PI3K in iTregs will shed light on the function of p55γ 
expression and may help to uncover novel signaling pathways important for iTreg 
differentiation.  To investigate the targets of p55γ in iTregs it should be possible to 
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immunoprecipitate p55γ and p85α in iTregs then run the immoprecipitates on a 2D gel.  
Differences in p55γ association proteins would suggest a different downstream target 
which could then be analyzed using mass spectrometry to identify the molecules. 
Identification of the downstream substrates of p55γ would be an exceptional molecular 
tool for understanding the differential signaling pathways in iTregs compared to 
conventional T cells. 
mTOR was found to have reduced activity upon TCR stimulation in iTregs, and 
its inactivation appears to be dependent upon an unknown phosphatase. Identifying this 
phosphatase would be beneficial in understanding the regulation of mTOR’s activity in 
iTregs and define a potentially druggable target.  Once the identity of this phosphatase is 
established, its inhibition would allow us to confirm its importance in iTreg generation. 
There is evidence to suggest that the phosphatase that could be regulating mTOR’s 
activity in iTregs is protein tyrosine phosphatase (SHP2). Ketroussi et al. described 
dephosphorylation of mTOR by SHP2 when human T cells were stimulated with a 
specific antigen (255). Therefore, it is plausible that this could also be occurring in our 
human iTregs positioning SHP2 as an attractive target for further investigation. PDK1 
was also found to be overexpressed in iTregs which could potentially compensate for the 
loss of AKT activity in response to TCR engagement in some downstream events.  AKT 
has been shown to be important in promoting survival in T cells. However AKT is not 
activated in response to the TCR in iTregs.  Even though there is a blockage of AKT 
activity in iTregs, the cells are a stable population in culture, suggesting that either there 
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is a low level of AKT activity or that PDK1 may offset AKT’s loss to induce survival of 
the cell. 
 Lastly, we have identified that AKT-SMAD3 associate in iTregs, and this 
association regulates SMAD3 activity. It will be critical to understand the physical 
association of AKT and SMAD3and if this interaction is required for iTreg development 
and function.  To test whether the AKT-SMAD3 interaction is fundamental for iTreg 
differentiation, we could generate a small molecule that is able to inhibit the ability of 
AKT to bind to SMAD3 through direct binding site competition.  Ideally, this small 
molecule would have a higher affinity for one or both members of the AKT-SMAD3 
complex than the strength of their natural interaction. As we have only seen this 
interaction occurring in iTregs, the presence of this small molecule should not have a 
negative effect on the function of other cells in the immune system. SMAD3-AKT 
interaction has been shown to occur in cell lines in vitro, however this is more than likely 
due to an artificial system were there was an overexpression of AKT and SMAD3 which 
may not occur physiologically in the cell. A pilot mouse study to determine if AKT-
SMAD3 interaction occurs in other tissue will help illuminate any potential interactions.  
We could then deliver this small molecule to iTregs in vivo in cases where iTreg 
localization is impinging on the ability of the immune system to recognize a tumor. Once 
inside the cell this small molecule should be able to cause AKT and SMAD3 to 
disassociate relieving SMAD3 transcriptional inhibition and subsequently inducing 
apoptosis of the cells and allowing the immune system to recognize and respond to the 
tumor. 
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6.6 Concluding Remarks 
 The mechanism of human iTreg development occurs in two steps (Figure 5.17).  
The first step requires the T cells to undergo a significant round of proliferation in which 
AKT is highly active and rapidly degraded. Additionally, TGF-β activates SMAD3 to 
induce the expression of FoxP3 during this sequence.  After proliferation, the cells start to 
differentiate into iTregs, where a rewiring of the signaling pathways occurs subsequently 
leading to the blockage of AKT and its cytoplasmic accumulation.  AKT accumulation 
will facilitate its association with SMAD3, thus negatively regulating SMAD3’s 
transcriptional activity.  As our results were demonstrated in human T cells, its clinical 
relevance and translational nature should not be understated. The work in this dissertation 
has elucidated several novel signaling molecules that are differentially regulated in iTregs 
compared to conventional T cells and has provided substantial basis for targeting 
signaling pathways to regulate iTreg development, function and maintenance. 
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